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Abbreviations 
ACTH             adrenocorticotropic hormone  
AHCY             S-adenosylhomocysteine hydrolase 
3-CHCA           α-cyano-3-hydroxycinnamic acid 
CID               collision-induced dissociation  
CRC              colorectal carcinoma 
DHB              2, 5-dihydroxybenzoic acid 
ESI               electrospray ionization  
HPLC             high pressure liquid chromatography 
3H4NBA          3-hydroxy-4-nitrobenzoic acid 
IHC               immunohistochemistry 
LGALS1          galectin1 
MALDI-TOF       matrix assisted laser desorption/ ionization time-of-flight  
MS               mass spectrometry  
NBS             2-nitrobenzenesulfenyl 
QIT              quadrupole ion trap 
RAN             ras related nuclear protein 
RCN1            reticulocalbin1  
2D-PAGE         two-dimensional polyacrylamide gel electrophoresis  
VIM              vimentin 
ZYX              zyxin 
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General Introduction 
 
The human genome sequence has been completely decoded and since then the 
genomes of many other species have been sequenced.  The focus of life science 
studies has accordingly been shifted to the investigation of structure and function of 
proteins.  Given that the genome is the “blueprint of life”, proteins can be considered 
the “actual performers of life”.  Therefore, elucidating the structures and function of 
proteins has become particularly important in life science research.  The word “protein” 
is derived from the Greek word “Proteios (protos)” which means “champion “ or “of first 
rank”.  This is very suggestive.  As the relationship between “genome” and “gene”, the 
total body of protein expressed in an organism is called its “proteome”, and the research 
of its field is referred to as “proteomics”.  The word “proteome” was coined by Mark 
Wilkins (1) and it has since been widely used.   
Although genomic information is indispensable in studying life science, this 
information alone is not sufficient to successfully drive research in this field.  The 
author believes that the breakthrough comes from studying proteins because in reality, 
proteins are the actual “players” in life.  Information from proteome, which shows 
dynamism of proteins in biological systems, is becoming more important and 
indispensable for pushing research in life sciences ahead.  To effectively drive life 
science research forward, a collaborative approach from genomic and proteomics 
studies is warranted. 
  Mass spectrometry has occupied the center of proteome research as the analysis 
technique of choice.  The author recognizes that it was an epoch-making event in 
protein research when the Nobel Prize was awarded to Koichi Tanaka and J.B. Fenn for 
their development of soft desorption ionization methods for mass spectrometric analysis 
of biological macromolecules.(2)  This opened the door to the rapid progress of 
research in the life science, particularly with regards to proteomics. 
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However, analysis of the proteome is difficult compared to that of the genome, owing 
to the labile nature of proteins, as well as the larger variety and wider dynamic range of 
their abundance in a cell or tissue system.  Hence, proteomic analysis requires further 
technical advances. 
With this in mind, the author devoted himself to develop novel method for proteomic 
differential display and to construct the “NBS Biomarker Discovery System”, in which 
the NBS (2-nitrobenzenesulfenyl) method is placed at the center of the system.  This 
method enables differential protein expression analysis between two states, such as 
disease and normal states.  It is also an important tool for the discovery of proteins 
associated with disease.  The author applied this new system to biomarker discovery 
using tissues of colorectal carcinoma (CRC) for biomarker discovery and obtained 
successful results.  
In the present thesis, the author describes the development of the NBS method, the 
construction of new proteome analysis system, and its application for clinical samples.  
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Chapter I: An approach to quantitative proteome analysis by labeling 
tryptophan residues 
I-1 Introduction 
Quantitative analysis of proteins has been achieved by a combination of protein 
separation with high-resolution 2D-PAGE (1) and tandem mass spectrometry based 
sequence identification.  From the viewpoint of the efficacy of 2D-PAGE, however, it is 
labor intensive and difficult to automate.  Furthermore, certain classes of proteins are 
excluded or under-represented in 2D-PAGE.  With the development of modern 
high-performance mass spectrometry using ESI and MALDI, together with separation 
instrumentation, higher sensitivity and speed are achieved in the identification of 
proteins after separation with gel-based techniques.  However, in the 2D-PAGE/mass 
spectrometry procedure, quantitative analysis of proteins is still hampered by the 
inherent flaws of gel-based separation (2).  Today, the quantification of relative protein 
abundance in two proteome samples is an active area in proteomics.  A growing 
number of reports have emerged in this field.  The methods involving metabolic 
labeling of proteins with an isotopically defined growth medium (3), and that using the 
isotope-coded affinity tag (ICAT) (4), are typical examples.  Also, a method of this kind 
designed specifically for phosphoproteins has been reported (5).  The ICAT method 
differs from the metabolic labeling method in that a stable isotope is incorporated within 
the labeling agent for the cysteine residues.  Very recently, a new method was 
reported to be capable of high accuracy and precision for protein abundance 
quantification (6, 7), which has promise as a general approach for quantitative profiling 
of isotopically labeled protein mixtures.  A major difference between our approach and 
that based on the ICAT strategy is that the former focuses on the tryptophan residue, 
which is one of the least abundant and most hydrophobic amino acid residues but which 
plays an important role in biological systems.  Our method employs one of the sulfenyl 
halide reagents, NBSCl (2-nitrobenzenesulfenyl chloride) (8, 9).  This type of reagent 
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has been found to be mild as well as selective for chromophoric modification of 
tryptophan and cysteine residues in proteins and peptides (10-12).  Of the two 
residues, labeling on tryptophan prevails over cysteine in acidic media (9).  On the 
tryptophan residue, the NBS moiety is introduced at the 2-position of the indole nucleus 
(Fig.Ⅰ-1).  Another difference between the present approach and the ICAT method lies 
in the use of an avidin affinity column to isolate the resulting cysteine-labeled peptides 
with the ICAT reagent.  In the case of the present method, the tryptophan residue is 
one of the most hydrophobic residues among those of the 20 amino acids (13).  
Therefore, tryptic fragments containing a tryptophan residue are hydrophobic and are 
known to have a relatively stronger affinity to Sephadex media;(13) further, fragments 
containing the NBS-labeled tryptophan are rendered even more hydrophobic and have 
still more tendency to be retained on the media, suggesting that isolation is possible 
with a Sephadex (e.g.LH-20) (13, 14) or reversed-phase column (14).  In the former 
case, the labeled peptides are isolated more efficiently because the Sephadex medium 
has an affinitive function as well as a sizing function (14).  The NBS method described 
here makes use of the Sephadex (LH-20) column for the separation of 
tryptophan-containing peptides after labeling.  This approach, using the chemically 
modified and concentrated tryptophan-containing peptides for LC/MS/MS analysis, has 
generated considerable interest in the field of proteomics.  This strategy using the NBS 
mass tag should be applicable to a wide range of proteomic samples because the 
presence of the NBS mass tag should not interfere with efficiency in CID in MS/MS 
experiments, or with the identification of the modified tryptophan-containing peptides 
using automated database search algorithms.  Because the target residue for labeling 
in the NBS approach is tryptophan, which is less abundant than the cysteine residue, 
our method generates less complex mass spectra than the ICAT method, thus 
facilitating analysis.  In this chapter, the author describes a method for quantitative 
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proteome analysis using a type of sulfenyl halide agent, NBSCl. 
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Ⅰ-2 Materials and Methods 
I-2-1 Chemicals and reagents 
Rabbit glyceraldehyde-3-phosphate dehydrogenase, rabbit phosphorylase b, chicken 
ovalbumin, bovine α-lactalbumin, chicken egg-white lysozyme, iodoacetamide, and 
a-cyano-4-hydroxycinnamic acid (CHCA) were purchased from Sigma (St. Louis, MO, 
USA).  Human ACTH (1-24) and rat galanin were from the Peptide Institute Inc. (Osaka, 
Japan).  Presenilin-1 (331-349)-Cys (human, mouse) was obtained from BACHEM AG 
(Bubendorf, Switzerland).  Two types of rat serum (GK/Crj and Crj: Wistar, from 
5-week-old males) were purchased from Charles River Japan, Inc. (Yokohama, Japan).  
The sulfenyl halide agent, 2-nitrobenzenesulfenyl chloride (NBSCl-12C6: light form), was 
purchased from Tokyo Kasei Kogyo Co., Ltd. (Tokyo, Japan). The method of synthesis 
of the heavy form (NBSCl-13C6) will be published elsewhere.  Tris (2-carboxyethyl) 
phosphine (TCEP) hydrochloride was obtained from Pierce (Rockford, IL, USA).  
Sephadex LH-20 was purchased fromAmersham Biosciences Corp. (Piscataway, NJ, 
USA).  Acetonitrile, acetic acid, formic acid, and trifluoroacetic acid (TFA) were 
purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan).  Hydrochloric 
acid, sodium dodecyl sulfate (SDS), tris(hydroxymethyl) aminomethane (Tris) and urea 
were purchased from Nacalai Tesque Inc. (Kyoto, Japan).  Sequencing-grade modified 
trypsin was obtained from Promega (Madison, WI, USA).  Water used in all 
experiments was purified using a MilliQ water purification system (Millipore Corporation, 
Bedford, MA, USA).  
 
I-2-2 MALDI-TOFMS analysis 
An AXIMA-CFR (Shimadzu/Kratos, Manchester, UK) instrument was used to obtain all 
of the MALDI-TOF mass spectra.  The operating conditions were as follows: nitrogen 
laser (337 nm); reflectron mode; detection of positive ions.  The instrument 
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incorporates a microchannel plate type ion detector.  The acceleration potential was 
set to 20 kV using a gridless-type electrode.  CHCA was used as matrix, and a 
saturated solution was prepared using 50% aqueous acetonitrile containing 0.05% TFA.  
A portion (2 µL) of each sample solution was mixed with 2 µL of the matrix solution, and 
an aliquot of 0.5 µL was immediately deposited on the target and dried completely.  
 
I-2-3 ESI-MS analysis 
An LCQ Deca XP ion trap mass spectrometer (ThermoFinnigan, San Jose, CA, USA) 
was used together with a Shimadzu LC-10ADvp solvent delivery system (Shimadzu 
Corporation, Kyoto, Japan).  Proteolytic peptides were separated on a 200 mm×50mm 
fused-silica capillary column (Magic C18; Michrom BioResources, Inc. Auburn, CA, 
USA) using an HPLC procedure employing a 60 min linear gradient starting with 5% of 
mobile phase A and ending with 80% of A (A: 5% aqueous acetonitrile containing 0.1% 
formic acid; B: 95%aqueous acetonitrile containing 0.1% formic acid ) at a flow rate of 5 
mL/min. The peptides were dissolved in 1% aqueous formic acid to achieve a 
concentration of ca. 50 mg/mL.  A 1 µL peptide mixture was pressure-loaded onto the 
column.  Eluting peptides were analyzed using µLC/MS and µLC/MS/MS techniques.  
The intensities of signals from eluting peptide pairs were measured with the scanning 
mass spectrometer.  To determine the amino acid sequence, the mass spectrometer 
was operated in a data-dependent MS/MS mode (16-18), in which a full-scan mass 
spectrum was followed by an MS/MS spectrum.  The precursor ions were dynamically 
selected for CID based on their intensity in the MS scan.  Peptides were identified by 
searching the MS/MS spectra against the appropriate databases using the computer 
program Sequest (19, 20).  Search parameters included a static modification of 
+152.98Da (2-nitrobenzenesulfenyl moiety) on tryptophan and +57.02Da (amidomethyl 
moiety from iodoacetamide) on cysteine.  The rat protein database from NCBI was 
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used in the search process.   
 
I-2-4 HPLC separation 
Retention time shifts of derivatized test peptides relative to non-derivatized peptides 
were measured using an HPLC system (LC-10ADvp solvent delivery system, Shimadzu 
Corporation) equipped with a 4.5_250mm C18 column (Shimpack VP-ODS; Shimadzu 
Corporation).  A 50 min binary gradient with 0–100% of solvent B (100% acetonitrile) 
was used.  Solvent A was 0.1M formic acid/triethylamine buffer (pH 4.5); a flow rate of 
1 mL/min was used.   
 
I-2-5 General procedure  
This method used two mixtures containing sample proteins at different concentrations 
derived from two different cell states.  Each mixture (protein content 100 mg each) was 
separately denatured using 15 µL of 0.1% SDS containing 5 mM EDTA solution (boiled 
for 5 min and left to cool down), then modified with a 20-fold molar excess of 
2-nitrobenzenesulfenyl chloride (the heavy reagent for one and the light reagent for the 
other) in 35 mL of acetic acid (left for 4 h in the dark at room temperature).  The two 
resulting labeled protein mixtures were combined, and excess reagent was removed 
(Sephadex LH-20, eluted with 30% aqueous acetonitrile), and then dried with a vacuum 
concentrator.  The resulting residue was dissolved in 50 µL of 50 mM Tris buffer (pH 
8.5) containing 0.1% SDS.  To this solution were added 5 µL of 40mM TCEP (left for 
30 min at 37℃), followed by 1 µL of 500 mM iodoacetamide (left for 45 min at ambient 
temperature in the dark).  Trypsin (dissolved in 450 µL of 50 mM Tris-HCl buffer, pH 
7.8, containing 5 mM CaCl2) was added to the resulting mixture to give an 
enzyme-to-substrate ratio of 1:10 (w/w).  The targeted tagged (tryptophan-containing) 
fragments in the tryptic peptide mixture were isolated using Sephadex LH-20, and 
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eluted with 30% aqueous acetonitrile.  The modified peptides thus obtained were 
analyzed with MALDI-TOFMS or ESI-MS. 
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I-3 Results and Discussion 
I-3-1 Principles of this approach 
The NBS reagent exhibits selectivity for the indole ring of tryptophan, and can 
incorporate a six-fold stable-isotopelabeled benzene nucleus (shown along with its 
general reaction scheme in Fig. I-1). This method consists of the following sequential 
steps (Fig. I-2):  (1) The tryptophan residues in a denatured protein sample 
representing one cell state are modified with the isotopically light form of the NBS 
reagent.  Protein samples from two conditions or states are labeled separately with the 
heavy and the light NBS reagent, combined, digested, concentrated, and then analyzed 
by mass spectrometry.  The equivalent residues in a sample representing a second 
cell state are modified with the isotopically heavy reagent.  (2) The two samples are 
combined and passed through a Sephadex LH-20 column to remove excess reagent 
and related small molecules. (3)  Disulfide bonds in the sample proteins are reduced, 
and the generated sulfhydryl groups are alkylated. (4)  The sample is then 
enzymatically cleaved to produce peptide fragments.  (5)The labeled (tryptophan 
containing) fragments are isolated using Sephadex LH-20 column chromatography.  
(6) In the last step, the isolated peptides are analyzed using MALDI-TOFMS or 
LC/ESI-MS.  The innovation in this approach is based on the selective reactivity of 
2-nitrobenzenesulfenyl chloride (8, 9) towards the indole ring of tryptophan.  Such 
reactivity is well known for some types of arylsulfenyl halides, including 
4-nitrobenzenesulfenyl chloride (10), 2,4-dinitrobenzenesulfenyl chloride (11), 
2-nitro-4-carboxybenzenesulfenyl chloride (12), and 2-nitrobenzenesulfenyl chloride 
(NBSCl).  Among these reagents, NBSCl has been frequently used and thoroughly 
investigated with respect to its near absence of reactivity with amino acid residues other 
than tryptophan and cysteine.  Of these two residues, the reaction is somewhat 
selective (but not specific) for the tryptophan residue over the cysteine sulfhydryl group.  
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Therefore, the cysteine residue is labeled as well with the reagent, in which the sulfenyl 
moiety attaches to the residue by means of a disulfide bond. 
However, if protein samples are processed as described above, any disulfide bonds 
that may have formed will be cleaved in the reduction step.  To confirm this hypothesis 
the author used a peptide, presenilin-1 (331-349)-Cys (human, mouse), which contains 
both tryptophan and cysteine residues (Fig. I-3).  This peptide (Fig. I-3 (a), m/z 2252.3) 
was modified with the sulfenyl chloride following the above procedure.  The molecular 
mass (Fig. I-3(b), m/z 2558.5) was increased by 306.2 Da, which indicates double 
labeling (i.e. on both residues, 153.1 Da for each 2-nitrobenzenesulfenyl moiety).  The 
doubly labeled peptide was then reduced and alkylated (iodoacetamide).  The 
molecular mass (Fig. I-3(c), m/z 2462.4) of the resultant peptide indicates that one NBS 
moiety was replaced by the amidomethyl moiety (57.0 Da).  In the reduction stage 
using TCEP, the disulfide bond is cleaved but the sulfide bond remains intact.  Thus, 
the author determined that the final peptide was derivatized with a NBS group on the 
tryptophan residue and an amidomethyl group on the cysteine residue.  From this 
result, the author reached the conclusion that the specific modification on the tryptophan 
residue was successfully achieved using the sequential procedure described above.   
 
 
 
 
Figure I-1. Structure and 
reaction of the NBS reagent.  
The reagent exists in two forms, 
heavy (contains six 
13
C) and light 
(contains no 
13
C). 
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Figure I-3. Specific introduction of the NBS moiety onto tryptophan residues.       
(a) Presenilin 1 (331–349)-Cys as the starting peptide; (b) a doubly derivatized starting peptide 
after treatment with NBSCl (light form); (c) the starting peptide with an NBS moiety on the 
tryptophan residue and an amidomethyl moiety on the cysteine residue after derivatization, 
reduction and alkylation. 
 
I-3-2 Application of this method to standard mixtures 
First, the author used human ACTH (1–24) and rat galanin as model 
tryptophan-containing peptides, and assumed two different cell states: state A 
consisting of ACTH/galanin.1:1 (molar ratio), and state B consisting of 
ACTH/galanin.1:2 (molar ratio).  The molar ratios for each of the two peptides 
Figure I-2. 
NBS strategy for quantifying differential  
protein expression.           
Protein samples from two conditions or states  
are labeled separately with the heavy and the  
light NBS reagent, combined, digested,  
concentrated, and then analyzed by mass  
spectrometry. 
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individually, between the samples, are 1:1 (ACTH) and 1:2 (galanin).  The peptide 
mixture representing state A was dissolved in 70% acetic acid.  A 20-fold molar excess 
of 2-nitrobenzenesulfenyl chloride (light reagent) was added to the solution, and the 
mixture was stirred for 4 h in the dark at room temperature.  The mixture representing 
state B was labeled with the heavy reagent using the same procedure.  The two 
postlabeling solutions were combined and purified with a Sephadex LH-20 column or a 
reversed-phase HPLC system.  The MALDI-TOF mass spectrum (Fig. I-4) shows that 
the observed ratios of the two components reflect the expected ratios well.  The 
changes in their respective retention times were 16.57–34.78 min (ACTH-labeled 
ACTH) and 21.78–35.27 min (galanin-labeled galanin).  The next application of this 
approach was performed with two mixtures containing the same four proteins at 
different concentrations (mg/15 mL): rabbit glyceraldehyde-3-phosphate 
dehydrogenase (12.5, 25); rabbit phosphorylase b (12.5, 25); chicken ovalbumin (12.5, 
25); and bovine alactalbumin (12.5, 25).  These two samples were processed 
sequentially according to the general procedure described above.  The isolated 
labeled peptides were quantified by their peak intensities in the MALDI-TOF mass 
spectrum, and their sequences were assigned by comparison with the theoretically 
digested fragments of the four proteins using trypsin.  The MALDI-TOF mass spectrum 
is shown in Fig. I-5 and the assigned peptide fragments are summarized in Table I-1.  
A plurality of labeled peptides was encountered for each protein.  The mean difference 
between the measured and predicted abundance ratios for light-labeled and 
heavy-labeled peptides (Table I-1) ranged between 2 and 12%, demonstrating the 
accuracy of quantification.  If some of the proteins are to be non-expressed in one or 
other of the control and perturbed samples (e.g. the ratios of the proteins are 1:0 or 0:1 
in the healthy cell and afflicted cell, respectively), the entire procedure should be 
performed separately for the two samples and analyzed using mass spectrometry.  
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The peptides of interest can then be discerned more clearly in the measured spectrum.   
  
 
Figure I-5. Relative quantification of a tryptic peptide in a four-protein mixture.                   
The MALDI-TOF mass spectrum of tryptic peptides of the four-protein mixture is shown; the inset 
shows an expanded view of a pair of labeled peptides (from rabbit phosphorylase b, EWTRMVIR). 
 
    
 
Table I-1. Sequence identification and quantification of components of a four-protein mixture 
Figure I-4. 
Relative quantification using ACTH and  
galanin as test peptides.  
(a) MALDI-TOF mass spectrum covering both heavy- and light-labeled 
peptides; (b) expanded view of heavy- and light-labeled ACTH, 
showing 1:1 ratio; and (c) expanded view of heavy- and light-labeled 
galanin, showing 1:2 ratio. 
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I-3-3 Spike test 
The spike test was performed to demonstrate that our method is applicable to 
biologically derived samples.  Two spiked samples were prepared as follows: state A 
contained 300 ng (21 pmol) of egg-white lysozyme in 5 mL of rat serum (Wistar), and 
state B contained 600 ng (42 pmol) of egg-white lysozyme in 5 mL of the same serum. 
The serum (5 µL) was assumed to contain 0.28 mg of total protein, of which the albumin 
content was 0.14 mg (2.1 nmol).  These two test samples were processed using the 
general procedure.  In the MALDI-TOF mass spectrum, two signals, separated by the 
expected 6Da (m/z 1198.74, 1204.72) and derived from the added lysozyme, were 
clearly observed, and the intensity ratio (100:48) was in good agreement with the 
theoretical value (100:50; Fig. I-6).   
 
 
I-3-4 Efficiency of Sephadex LH-20 isolation 
The increment in the hydrophobicity of a tryptophan-containing fragment after 
modification using NBS reagent enabled us to employ Sephadex LH-20 for the isolation 
of labeled fragments.  Two samples, each of 5 µL of Wistar rat serum, were used and 
assumed to represent two biological states.  The two were processed using the 
general procedure described above.  Half of the resultant peptide mixture was applied 
to the Sephadex LH-20 column (bed volume 2 mL).  The eluent was 30% aqueous 
acetonitrile and the fractionation volume was 130 µL.  The elution profile is partly 
shown in Figs. I-7(b)–(e), with the paired peaks clearly discernable with a 6 Da 
Figure I-6. MALDI-TOF mass spectrum of spiked sample.                
The spectrum shown is that of a derivatized synthetic tryptic  
peptide (GTDVQAWIR, 117-125 from egg-white lysozyme)  
which was added to rat serum (Wistar) as a spike.   
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difference in Figs. I-7(c) and (d); the target tryptophan-labeled peptides eluted between 
fraction numbers (19-26). 
 
 
 
I-3-5 Co-elution of heavy- and light-labeled peptides in reversed-phase 
HPLC 
The differential elution of the light- and heavy-isotope labeled peptides could cause 
significant difficulty in identifying or quantifying the peptide pairs.  For this reason, the 
author investigated the elution profile of NBS-labeled (light and heavy) peptide 
fragments.  The peptide used was a tryptic fragment of egg-white lysozyme, 
GTDVQAWIR (117–125), which was synthesized by the Fmoc method using a PSSM-8 
peptide synthesizer (Shimadzu Corporation).  The peptide was then modified to give 
the same amount of light- and heavy-labeled peptides.  These two samples were 
mixed and passed through the Sephadex LH-20 column.  The resultant peptide 
mixture was analyzed using reversed-phase HPLC as described in “Section I-2-3”.  
The heavy- and light-labeled peptides co-eluted (Fig. I-8), and sequencing using the 
MS/MS technique was successfully achieved (Fig. I-9). 
Figure I-7. Elution profile of derivatized 
Wistar rat serum using LH-20.      
(a) MALDI-TOF mass spectrum of the tryptic 
peptide mixture before fractionation and 
concentration with LH-20.  
(b)–(e) MALDI-TOF mass spectra for some 
LH-20 fractions.  Pair peaks (6 Da 
separation) are clearly seen for fractions 
19 and 20. 
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I-3-6 Application of the method in quantitative analysis of protein 
expression under different conditions  
The NBS method was applied to study the differences in protein expression in rat serum 
(Rattus norvegicus).  The author compared protein expression in the serum of a 
control rat (Crj: Wistar) and a hyperglycemic rat (GK/Crj).  The blood glucose level of 
the hyperglycemic rat was 372 mg/dL.  A 2-µL sample (total protein content 100 µg) of 
each serum was treated using the procedure described in “Section I-2-5” (light-labeling 
for the serum from Wistar, heavy-labeling for GK).  The isolated labeled peptides were 
quantified and sequenced by µLC/MS and µLC/MS/MS experiments using an ESI 
iontrap mass spectrometer.  Three peptides were sequenced as follows: (1) AWAVAR 
(m/z 826.5, 832.5); (2) WKIRK (m/z 883.5, 889.5); and (3) NTAAWAK (m/z 914.5, 
920.4).  The observed intensity ratios (Wistar/GK) of the three peptides, calculated 
from the integration of the corresponding extracted mass chromatogram peaks, were all 
Figure I-8. Co-elution LC/MS profile of a 
derivatized tryptic peptide (GTDVQAWIR, 
117-125 from egg-white lysozyme).        
 Heavy- and light-labeled peptides practically co-elute  
from a Magic C18 (Michrom BioResources, Inc.)  
fused-silica capillary column. 
 
Figure I-9. Sequence identification of a tryptic 
peptide (GTDVQAWIR, 117-125 of 
egg-white lysozyme).                                 
The example shown is the identification of  
the amino acid sequence for the peptide for  
which the abundance was measured in Fig.I-6.  
The y-ions are shown together with their m/z  
values; b-ions are also annotated. 
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close to 1.  The identified proteins were albumin, purinergic receptor P2X, and 
transferrin, respectively.  The ESI mass spectrum (range m/z 650–1050) obtained for 
the LC peak for the two labeled forms of the peptide AWAVAR (m/z 826.5 and 832.5 for 
peptides in which the tryptophan residue is respectively light- and heavy-NBS-labeled), 
is shown in Fig. I-10(a).  Reconstructed mass chromatograms for the peptide pair (m/z 
826.5 and 832.5) are shown in Fig. I-10(b), where the peaks appear serrated because 
the mass spectrometer switched between the MS and the MS/MS modes once per 
second to generate the CID mass spectrum of a selected peptide ion for the 
identification.  This methodology has been developed to avoid SDS-PAGE  
separation because of its inherent drawbacks, as stated above.  However, in treating 
complex protein mixtures (e.g. rat serum), pre-separation seems to be desirable. In this 
regard, the author is now investigating the effectiveness of pre-separation procedures 
(e.g. SDS-PAGE, etc.) in order to obtain better results. 
 
 
Figure I-10. Quantitative analysis of a protein from a rat serum sample.              
(a) Full-scan (m/z500–1000) mass spectrum obtained at retention time 17.40 min in the mLC/MS/MS 
mixture analysis.  Three different peptide doublets (6 Da separations), eluting from the column, are shown. 
(b) Expanded view of extracted mass chromatograms, showing the relative abundance of the peptide pair 
(m/z 826.5, 832.5).  The ratio of the calculated areas (0.99:1) was used to determine the relative peptide 
quantities. 
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In conclusion, the author demonstrated the feasibility of using the NBS reagent for 
quantitative analysis of protein mixtures and identification of the protein components. 
The potential of this method lies in the following aspects: (1) the ability to specifically 
introduce the NBS moiety onto the tryptophan residue; (2) the efficient and simplified 
isolation of NBS-labeled peptides owing to their highly hydrophobic nature; (3) the 
co-elution of the isotopically light- and heavy-labeledpeptides; (4) the accurate 
quantification of a complex protein mixture using the stable isotope dilution approach; 
(5) successful sequence identification owing to the compatibility of the NBS label with 
this technique; and (6) the reduction of data complexity because of the relative scarcity 
of tryptophan residues in proteins.  Several methods have been published using 
isotope dilution for protein quantification.  Each method has its strengths and 
limitations.  Thus, the 15N-labeling method is only applicable to cells grown in culture.  
The ICAT method may have difficulties if applied to other separation techniques 
because it was developed specifically for use with affinity purification; also the labeling 
on cysteine residues implies that it is not applicable to cysteine-free proteins.  The 
present NBS method has its own strengths and limitations. Tryptophan-free proteins 
cannot be the target of this method.  The scarcity of tryptophan residues in proteins 
might in turn be the cause of poor results, in particular with proteins of low abundance.  
To overcome these limitations of each methodology, and to obtain more reliable 
outcomes, one method should be employed in combination with another method, or with 
conventional separation techniques such as SDS-PAGE.  The present method 
presents a universal approach for the analysis of biological systems and pathways in 
cells, tissues, and organisms. 
In this chapter, the author developed a novel quantitative proteome technique (the 
NBS method) and demonstrated that it is useful for quantitative proteome analysis.  
However, the procedure had to be optimized for the improvement in the efficiency of the 
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analysis.  Then, in Chapter II, the author optimized the protocol of the method and 
improved the efficiency of enrichment for NBS-labeled peptides. 
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Chapter II: Improved the NBS method: optimization of the protocol and 
improved enrichment for labeled peptides 
II-1 Introduction 
Both the feasibility of the NBS reagent for quantitative analysis and the potential of this 
method were shown in Chapter I ; however, the procedure has since been optimized.  
If the protocol is performed exactly as described in Chapter I, a considerable amount of 
the sample may be lost during the procedure.  Furthermore, peaks that were increased 
by 57 m/z units from their original values were observed in the mass spectra, and 
several unlabeled peptides were eluted along with the labeled peptides.  The author 
therefore revised and improved each reaction throughout the protocol.  Because the 
use of detergents is often poorly compatible with trypsin digestion and/or mass 
spectrometric measurement,(1) the concentration of sodium dodecyl sulfate (SDS) was 
kept low (0.1%) in the original protocol (Chapter I).  However, it is obvious that this 
concentration of SDS was too weak to denature all of the proteins in the sample, and it 
is also difficult to keep denatured proteins soluble.  Thus, limitations of the original 
denaturing conditions resulted in some sample loss.  Instead, the author used 8 M urea 
and/or 6 M guanidine hydrochloride (GdnHCl), both of which are strong denaturants 
widely used for various protein studies that can be easily removed by desalting or by 
reversed-phase liquid chromatography (RP-LC).  This concentration range is strong 
enough to denature and solubilize most of the proteins, and is also high enough to keep 
those denatured proteins from aggregation.  In addition, even a high concentration (4 
M) of urea is compatible with trypsin digestion. (1) In the first half of this study, the 
sample loss and other defects seen in the original protocol were examined.  In the 
original NBS method, targeted peptides having NBS-labeled tryptophan residue(s) were 
enriched by an LH-20 column.  This procedure took advantage of the relatively 
stronger affinity of tryptophan-containing peptides for Sephadex media (LH-20), as well 
as additional changes in hydrophobicity and chromatographic mobility induced by the 
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reaction with NBSCl. (2)  However, several non-labeled peptides were also co-eluted 
with the labeled peptides.  Here, the author utilized a phenyl resin, which is generally 
used for hydrophobic interaction chromatography and RP-LC, in an attempt to enrich for 
the NBS-labeled peptides.  Because the NBS-tryptophan moiety is not only 
hydrophobic but is also aromatic, π-electron interactions between phenyl groups of the 
column and the NBS-tryptophan moiety of the labeled peptides are likely to be more 
specific, and hence the use of a phenyl column should be advantageous for the 
enrichment step.  In fact, the importance of π-π interactions in the special selectivity of 
a phenyl column for an aromatic solute, and in addition an increase in the selectivity 
achieved by nitro substitutions in aromatic rings, have been reported. (3)  In the latter 
half of this study, the efficiency of enrichment for NBS-labeled peptides using a phenyl 
column was examined. 
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II-2 Materials and Methods 
II-2-1 Chemicals and reagents 
Chemicals and reagents used in this study were mostly the same as described in 
Chapter I.  HiTrap phenyl FF (high sub), HiTrap phenyl HP and phenylsepharose HP 
were purchased from Amersham Biosciences (Uppsala, Sweden) and were used as a 
‘phenyl column’.  Urea and guanidine hydrochloride (GdnHCl) were purchased from 
Bio-Rad (Hercules, CA, USA) and Sigma, respectively.  The protease inhibitor cocktail 
and phosphatase inhibitor cocktails I and II were purchased from Sigma.  Sample 
preparation ‘4 protein mix’ and ‘liver extract’ samples Mixtures of proteins containing 
α-lactalbumin (bovine), glyceraldehyde-3-phosphate dehydrogenase (rabbit), lysozyme 
(chicken) and ovalbumin (chicken) (25 µg each, purchased from Sigma) were prepared 
and used as ‘4 protein mix’ samples. Mouse (C57BL/6JJcl, 10 weeks, male) liver 
tissues purchased from CLEA Japan (Tokyo, Japan) were crushed to powder by a 
mortar and pestle, with the samples kept frozen by liquid nitrogen. A portion of the 
crushed powder was suspended in lysis buffer (50 mM TrisHCl (pH 8.0), 50 mM NaCl, 1 
mM EDTA containing the protease inhibitor cocktail (1/200 v/v) and phosphatase 
inhibitor cocktail I and II (1/100 v/v each)) and homogenized using a sample grinding kit 
(Amersham Bioscience) on ice.  The lysate was separated by centrifugation at 20,000
×g for 45 min to yield a supernatant that was used as the ‘liver extract’ sample.  
Protein concentration was determined by a BCA kit (Pierce, Rockford, IL, USA) using 
bovine serum albumin as a standard protein. 
 
II-2-2 For the “sample recovery assay” 
Pairs of ‘4 protein mix’ or ‘liver extract’ samples were suspended in 0.1% SDS solution 
containing 5 mM EDTA followed by boiling for 3 min, or suspended in 8 M urea solution 
containing 5 mM EDTA or 6 M GdnHCl solution containing 5 mM EDTA followed by 
vortex mixing at room temperature.  Pairs of denatured proteins were labeled with 
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either NBSCl (heavy) or NBSCl (light) reagent, followed by mixing of heavy- and 
light-labeled samples and desalting with an LH-20 column.  A portion of each sample 
was separated by sodium dodecyl sulfate/polyacrylamide gel electrophoresis 
(SDS-PAGE). 
 
II-2-3 For the “tryptic digestion optimization assay” 
NBS-labeled and desalted samples prepared as in ‘Sample recovery assay’ were 
lyophilized and resuspended in 50 µL of 8M urea or 6M GdnHCl, each containing 50mM 
Tris-HCl (pH8.8) (the same denaturant as used in ‘sample recovery assay’ was used).  
After being reduced and alkylated, each sample was adjusted to a final concentration of 
0.6, 1.2, or 2.0 M GdnHCl or 0.8, 1.6, or 4.0 M urea, and tryptic digestion 
(trypsin/substrate.1:20 w/w) was carried out in a 500 µL volume at 37℃ for 16 h.  An 
equivalent sample containing 40 µg of each digest was separated by SDS-PAGE. 
 
II-2-4 For the “+57 Da peak assay” 
A pair of ‘4 protein mix’ samples was labeled with NBS reagent and desalted according 
to the improved protocol using 8 M urea as denaturant.  These samples were reduced 
and alkylated followed by tryptic digestion according to either the original protocol (in a 
0.01% SDS solution) or the improved protocol (in an 8 M urea solution).  Acetonitrile 
was added to a final concentration of 25% in the original protocol to improve the 
efficiency of digestion.  Both tryptic digests were fractionated using a phenyl column 
according to the improved protocol. 
 
II-2-5 For the “enrichment column evaluation assay”  
A tryptic digest of the NBS-labeled ‘4 protein mix’ samples was prepared according to 
the improved protocol using 8 M urea (in both the first denaturation and the second 
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denaturation steps).  This digest, containing both NBS-labeled and non-labeled 
peptides, was fractionated using either a Sephadex LH-20 column (2 mL) or a phenyl 
sepharose HP column (1 mL) to enrich for the labeled peptides.  For the LH-20 column, 
the digest was loaded onto a column pre-equilibrated with 30% aqueous acetonitrile and 
was eluted by continuous addition of 500 mL of 30% aqueous acetonitrile (Fr.1–Fr.10).  
For the phenyl column, the digest was loaded onto a column pre-equilibrated with 0.1% 
trifluoroacetic acid (TFA) and washed with 1 mL of 0.1% TFA three times (W1–W3). The 
labeled peptides were then eluted as 1mL fractions using a step-wise gradient of 
increasing acetonitrile (10, 15, 20, 25, 30, 35, 40%; EL1–EL7) containing 0.1% TFA.  
As eluted fractions from LH-20 contain both peptides and salts, desalting using a Zip Tip 
µ-C18 was performed, and 0.5 µL of each desalted sample was subjected to analysis by  
MALDI-TOF MS.  In the case of the phenyl column, however, only wash fractions 
(W1–W3) contain salts, and these samples were desalted before MALDI-TOFMS 
analysis, whereas 0.5 µL of each eluted fraction (EL1–EL7) was directly analyzed by 
MALDI-TOF MS. 
 
II-2-6 For the ‘overall comparison assay’ 
A pair of ‘liver extract’ samples was labeled with NBS reagent, desalted, reduced, 
alkylated, digested by trypsin, and fractionated on an enrichment column according to 
the original NBS protocol2 and the improved NBS protocol described here.  Each 
fraction was concentrated ten-fold and 0.5 mL was subjected to MALDI-TOF MS 
analysis.  Desalting using a Zip Tip µ-C18 was performed if needed.  
 
 
II-2-7 SDS-PAGE  
In the ‘sample recovery assay’, a portion of the desalted sample was lyophilized and 
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resuspended in SDS sample buffer (1% SDS, 50 mM Tris-HCl (pH 6.8), 50mM NaCl, 
5% β-ME).  In the ‘tryptic digestion optimization assay’, reactions were stopped by the 
addition of a nine times volume of acetone.  The precipitates were washed with 
acetone and then solubilized in SDS sample buffer by boiling for 5 min.  These 
samples were separated by SDS-PAGE using 12.5% acrylamide gels and the 
discontinuous buffer system of Laemmli to separate the ‘4 protein mix’ samples, and 
15% gels to separate the ‘liver extract’ samples. (4)  The Precision Plus Dual Standard 
(Bio-Rad) was used as a molecular weight marker in electrophoresis. Protein bands 
were stained with Coomassie Brilliant Blue R-250. (4)  
 
II-2-8 MALDI-TOFMS analysis 
All of the mass spectra were obtained using a MALDI-TOF mass spectrometer, 
AXIMA-CFR plus (Shimadzu, Kyoto, Japan/Kratos, Manchester, UK). Detailed 
conditions were described in “Chapter I”.  CHCA and 3H4NBA were dissolved in 0.1% 
TFA containing 50% acetonitrile at the concentration of 10 mg/mL to make matrix 
solutions.  The CHCA solution was used to analyze the ‘4 protein mix’ samples, 
whereas a co-matrix containing a CHCA and 3H4NBA solution (1:1 v/v) was used to 
analyze the ‘liver extract’ samples.  
 
II-2-9 Improved NBS procedure 
Two sample mixtures containing the same set of proteins were prepared.  Each 
mixture (100 mg of proteins) was dried separately and then denatured by dissolving in 
25 mL of denaturation solution (6 M GdnHCl or 8 M urea, each containing 5 mM EDTA).  
After dissolving the dried samples by using a vortex mixer, the NBSCl heavy solution 
(0.17 mg of heavy reagent (13C6-NBSCl) in 25 mL of acetic acid) was added to one 
protein solution and the NBSCl light solution containing the light reagent (12C6-NBSCl) 
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was added to the second protein solution.  These protein solutions were then 
incubated for 1 h at room temperature in the dark.  The two labeled protein mixtures 
were then combined, and excess reagent and denaturant were removed using 
Sephadex LH-20.  The protein mixtures (100 mL) were loaded onto an LH-20 column 
(500 µL) preequilibrated using 30% aqueous acetonitrile, and the flow-through was 
discarded.  Then an additional 100 µL of 30% aqueous acetonitrile was loaded, and 
again the flow-through was discarded.  The labeled proteins were eluted by adding 
another 200 mL of 30% aqueous acetonitrile.  The eluate (200 µL) was lyophilized and 
resuspended in 48 mL of resuspension solution (6 M GdnHCl or 8 M urea, containing 
50mM Tris-HCl (pH 8.8)).  After adding 1 mL of 200 mM tris(2-carboxyethyl) phosphine 
hydrochloride (TCEP) as a mild reducing reagent, the solution was incubated for 30 min 
at 37℃, then 1 µL of 500 mM iodoacetamide (IAA) was added and the solution was 
incubated for 45 min at room temperature.  Trypsin was dissolved in 450 mL of 50 mM 
Tris-HCl (pH7.8) containing 5 mM CaCl2 and added to the reduced and alkylated protein 
mixture to give an enzyme-to-substrate ratio of 1:20 (w/w), followed by incubation at 
37℃ for 4–16 h.  NBS-labeled tryptophan-containing peptides in the tryptic digest 
were isolated using a phenyl column (HiTrap phenyl column or 1mL of phenyl 
sepharose HP) pre-equilibrated with a 0.1% TFA solution.  Next, 5 µL of a 10% TFA 
solution were added to the sample and it was loaded onto the column, then washed 
three times with 1mL of 0.1% TFA.  Elution was performed with 1 mL of the 0.1% TFA 
solution containing increasing concentrations of acetonitrile, from 10% to 40% with a 5% 
interval.  Each eluted fraction was analyzed directly by MS. 
 
II-3 Results and discussion 
As mentioned above, this improved protocol differs from our original procedure primarily 
at two points.  One is that we changed the denaturant from SDS to urea or GdnHCl, 
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and the second is that the enrichment is now on a phenyl column rather than an LH-20 
column.  These changes necessitated concomitant changes of reaction conditions for 
labeling of protein samples, reduction, alkylation, and tryptic digestion of the labeled 
proteins, and also for enrichment of the labeled peptides.  To determine the best 
conditions for each reaction and to confirm the improved efficiency, the author now 
divides the protocol into three steps and examine each step separately. (Fig. II-1) 
 
 
 
II-3-1 Improved sample recovery using urea or GdnHCl as denaturant 
In step 1, the author examined the procedure from the denaturation of the protein 
samples to the desalting. (Fig. II-1)  In the improved method, the reagent for 
solubilization and denaturation was changed from 0.1% SDS to 8 M urea or 6 M 
GdnHCl to keep the denatured proteins soluble and also to improve the labeling 
efficiency.  The main purpose of the next desalting step is to remove excess labeling 
reagent.  At the same time, exchange of buffer and/or solvent is also important to 
control the conditions for the following reactions.  If these denaturing solutions are 
Figure II-1. Flow chart showing the NBS 
procedure.    The procedure was divided into 
three steps and each step was separately optimized 
and evaluated for sample recovery (step 1), for 
efficiency of digestion and existence of the 57 Da 
modification (step 2), and for efficiency of 
enrichment for NBS-labeled peptides (step 3). 
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used as a running solution in the desalting step, too much denaturant will remain in the 
eluted sample, because the volume at the reduction step is four times less than that of 
the desalted eluate.  Furthermore, if a solution without denaturant is used as a running 
solution, the denatured proteins will aggregate and be lost.  Therefore, a 30% aqueous 
acetonitrile solution, which can easily be evaporated but can keep denatured proteins 
soluble, was used as a running solution in the desalting step.  As a result, the loss of 
samples was negligible in this step, regardless of whether the denaturant was urea or 
GdnHCl, and samples without salt or denaturant were thus obtained. (Fig. II-2)  The 
labeling efficiency was almost complete (higher than 95%) and the reaction was almost 
completed in less than 10 min in the case of the ‘4 protein mix’ (data not shown).  It 
should be noted that one must use a freshly prepared urea solution made of high-grade 
reagent and never incubate at high temperature, otherwise carbamylation will occur and 
+43 m/z unit peaks will appear. (5)  The use of thiourea should be avoided to solubilize 
protein samples, because the labeling reaction will be incomplete (probably because 
the NBS reagents are quenched by thiourea).  One advantage of the NBS method is 
that it reduces the complexity of the analysis, because the number of tryptophan 
residues in one protein is small, and hence the number of the labeled peptides to be 
analyzed is also small.  On the other hand, this means that accurate quantitation of 
each paired peak is required.  By using this improved protocol, suppression of the 
sample loss was achieved, as mentioned above, and as a result the degree of 
quantitation was also improved (The standard deviation of ratios from a data set 
obtained using the improved protocol decreased to about a half to a third of values 
obtained using the original protocol; data not shown.). 
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Figure II-2. Recovery of the protein samples after labeling and desalting.  
(a) Protein samples were prepared using the ‘4 protein mix’ as described in Sample preparation for ‘sample 
recovery assay’. The denaturants used were 0.1% SDS (S; lane 3), 8M urea (U; lane 4), or 6M guanidine 
hydrochloride (G; lane 5), respectively. One twentieth of the desalted sample was applied to a gel and 
subjected to SDS-PAGE analysis (lanes 3–5). Starting samples corresponding to the same amount (10 mg; 
lane 1) and one-fifth of this amount (2 mg; lane 2) were also applied. It should be noted that migration of 
each protein was retarded, as the molecular mass increases upon NBS labeling. Abbreviations: Ova, 
ovalbumin; G3P, glyceraldehyde-3-phosphate dehydrogenase; Lys, lysozyme; a-lact, a-lactalbumin. (b) 
The same set of experiments was carried out using ‘liver extract’ as a starting sample. One-tenth of the 
desalted sample (lanes 3–5) and a corresponding starting sample of 20 mg (lane 1) and 4 mg (lane 2) were 
applied to a gel and subjected to SDS-PAGE analysis. 
 
II-3-2 Optimization of the conditions for trypsin digestion 
In step 2, the author examined the procedure from the second denaturation to tryptic 
digestion (Fig. II-1).  The reaction conditions for reduction, alkylation and digestion of 
the labeled proteins were optimized.  First, the desalted and dried sample proteins 
were re-solubilized using denaturing buffer (8 M urea or 6 M GdnHCl, containing 
Tris-HCl).  In this condition, both the reduction of disulfide bonds by TCEP and the 
alkylation of free sulfhydryl groups by IAA were confirmed to occur satisfactorily (data 
not shown).  However, under the same condition, proteases are denatured or their 
activities are affected by such a high concentration of denaturant, resulting in partial 
cleavages and/or mistakes in the recognition of cleavage sites.  Therefore, the author 
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examined how many times the solution should be diluted to optimize the digestion.  As 
shown in Fig. II-3, a final concentration of 0.6 M for GdnHCl and 0.8 to 4.0 Mfor urea 
seemed to be favorable. From the MS analysis, 0.8 and 1.6 M urea is recommended, 
because partially cleaved fragments and unidentified peaks were sometimes observed 
for 0.6 M GdnHCl and 4.0 M urea (data not shown).  The author concluded that urea is 
an appropriate denaturant for tryptic digestion of proteins, and its optimum dilution is 
5–10 times.  
 
 
 
Figure II-3. Determination of optimum conditions for trypsin digestion. (a) Protein samples were prepared 
using the ‘4 protein mix’ as described in Sample preparation for ‘tryptic digestion optimization assay’. An 
equivalent sample containing 40 mg of each digest under the denaturing conditions shown in the figure was 
separated by SDS-PAGE (lanes 2–7); 10 mg of the undigested samples were also applied to the gels as a 
control (C; lane 1). Asterisk indicates the modified trypsin used for digestion. Abbreviations used are the 
same as in Fig. 2. (b) The same set of experiments was carried out using ‘liver extract’ as a starting sample. 
 
II-3-3 Decrease in 57 m/z larger paired peaks caused by side reactions of the 
alkylating reagent  
In mass spectra obtained from the original NBS protocol, paired peaks larger by 57 m/z 
units than the theoretical paired peaks were observed (Fig. II-4, upper lane).  In the 
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original protocol, a step for removal or quenching of excess IAA, a reagent used for the 
alkylation reaction, was omitted. IAA reacts mainly with free sulfhydryl groups of 
cysteine, but is also known to react with histidine, lysine, tyrosine, and methionine under 
some conditions. (6)  From this information and our observations, the author assumed 
that the peaks larger by 57 m/z units corresponded to the peptides in which an 
unexpected alkylation had occurred on a side chain other than the cysteine SH group.  
The author found that the appearance of these larger peaks could be suppressed by 
quenching with SH reagents or by removing the alkylation reagent by desalting or 
acetone precipitation (data not shown). 
On the other hand, in mass spectra obtained from the improved NBS protocol, such 
paired peaks larger by 57 m/z units were no longer seen, and additional manipulations 
were unnecessary (Fig. II-4, lower lane).  The author speculates that the amino groups 
of the denaturants urea or GdnHCl acted as buffers for the alkylation reaction, thus 
suppressing the side reactions of IAA. 
 
Figure II-4. Elimination of the byproduct peaks corresponding to molecules with mass increased by 57 Da 
from the original mass. Samples were prepared as described in Sample preparation for ‘þ57 Da peak 
assay’ using 0.01% SDS (upper panel) or 8M urea (lower panel), respectively, and were subjected to 
MALDI-TOFMS analysis. Parts of the mass spectra for the two eluted fractions corresponding to EL3 (left 
panel) and EL6 (right panel) are shown. Arrows indicate the peaks shift by 57 m/z units (upper panels). 
Paired peaks observed at m/z 1198.5 and 1204.5 in the left panel correspond to a peptide (GTDVQAWIR) 
derived from lysozyme, and those observed at m/z 1353.6 and 1359.6 in the right panel correspond to a 
peptide (VGINYWLAHK) derived from a-lactalbumin. 
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II-3-4 Improved enrichment for NBS-labeled peptides using a phenyl column 
In step 3, the author examined the last part of the procedure, enrichment for labeled 
peptides (Fig. II-1).  In the original NBS method, an LH-20 column was used for 
enrichment and many labeled peptides were eluted in the mid to late fractions (Fr. 4–9 
in Fig. II-5(a)).  However, some non-labeled peptides were co-eluted with the labeled 
peptides in the mid fractions (Fr.4–Fr.6 in Fig. II-5(a)).  In addition, recovery of the 
labeled peptides was not sufficient, so peptides 3 and 9 were only marginally detected 
in Fr.6 and Fr.5, respectively. 
Here, the author searched for other chromatographic media and tried to utilize a 
phenyl resin to enrich for the labeled peptides.  As shown in Fig. II-5(b), the 
enrichment of labeled peptides was apparently improved.  Advantageous points of the 
phenyl column are listed below.  First, contamination with unlabeled peptides was 
reduced.  Most of the unlabeled peptides were eluted in the washing step (W1–W3), 
and the eluted fractions (EL1–EL7) contained almost exclusively the labeled peptides.  
This clearly contributed to the discrimination of single peaks as non-paired labeled 
peptides rather than unlabeled contaminating peptides. Second, recovery of the labeled 
peptides was increased.  Even if only ‘Elute’ fractions (EL1–EL7) were collected, the 
recovery rate of the labeled peptides reached 80–90%, as determined by the NBS 
absorbance at 360 nm (data not shown).  Third, as small molecules like salts and 
buffers were removed in the ‘Wash’ fractions (W1–W3), the eluted fractions (EL1–EL7) 
could be directly measured by MS.  In the previous LH-20 purification, desalting was 
needed before measurement because the labeled peptides and salts were co-eluted. 
Fourth, individual NBS-labeled peptides were separated from each other to some extent.  
Using a capillary-type phenyl column, both the isolation of labeled peptides from 
unlabeled peptides and the fractionation between labeled peptides can be achieved at 
the same time.  Fifth, the potential capacity of the phenyl column is expected to be 
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much higher than that of an affinity column, because a small ligand such as a phenyl 
group can be attached to the resin at a high concentration.  This feature is more 
significant in the purification of peptides compared to that of proteins, because the mass 
ratio of the target molecule and tag moiety is relatively low. In fact, a similar level of 
purification was obtained, with the same efficiency and the same recovery rate, when 
four times the original amount of sample was loaded (data not shown). 
The aromaticity of the NBS-tryptophan moiety is exploited in the phenyl column 
chromatography.  One might think that peptides containing tyrosine and phenylalanine 
residues would preferentially interact with the phenyl resin and be eluted in the relatively 
late fractions. However, unlabeled peptides containing tyrosine and/or phenylalanine 
residues were all found in the ‘Wash’ fractions, and they were well separated from the 
labeled peptides (among the 14 peaks encircled by red dashed lines in Fig. II-5, five 
peaks corresponded to peptides containing two of these residues (Tyr and Phe) and six 
peaks to peptides containing one of them).  The author mentions that the author has 
succeeded in making a monoclonal antibody specific to the NBS moiety (unpublished 
results).  However, an affinity column made using this monoclonal antibody was not 
superior to the phenyl column in that its recovery rate was not higher.  Therefore, use 
of the phenyl column is more efficient and economical. 
 
 
 
 
 
 
 
 44 
 
Figure II-5. Enrichment for the NBS-labeled peptides by Sephadex LH-20 versus phenyl sepharose.  
Samples were prepared as described in Sample preparation for ‘enrichment column evaluation assay’ 
using an LH-20 column (a) or a phenyl column (b), respectively.  A portion of each eluted fraction 
(Fr.1–Fr.10) from the LH-20 column and each washed fraction (W1–W3) and eluted fraction (EL1–EL7) 
from the phenyl column was subjected to MALDI-TOFMS analysis.  Paired peaks corresponding to 
NBS-labeled peptides are encircled by blue lines and single peaks corresponding to non-labeled peptides 
are encircled by red dashed lines. Numbers in parentheses indicate theoretical 12 NBS labeled peptides 
observed between m/z 600 and 2400. The monoisotopic masses of the light derivatives, the peptide amino 
acid sequences, and the proteins from which they originated are listed below. Numbers in angled brackets 
(<3> and <9> in (a)) indicate weak detection of the peaks. (1) 627.27, LWR (glyceraldehyde-3-phosphate 
dehydrogenase;G3P); (2) 759.29, EWTR (phosphorylase b); (3) 785.33, GLWEK (ovalbumin); (4) 1198.53, 
GTDVQAWIR (lysozyme); (5) 1244.51, LDQWLCEK (a-lactalbumin); (6) 1299.38, WWCNDGR (lysozyme); 
(7) 1353.64, VGINYWLAHK (a-lactalbumin); (8) 1478.62, GYSLGNWVCAAK (lysozyme); (9) 1734.71, 
LTEWTSSNVMEER (ovalbumin); (10) 1916.79, LISWYDNEFGYSNR (G3P); (11) 1981.78, 
IVSDGNGMNAWVAWR (lysozyme); (12) 2011.95, ELINSWVESQTNGIIR (ovalbumin). 
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II-3-5 Increase in the total number of observed paired peaks 
Finally, the author compared the protocol described here with the original one in the 
analysis of mouse liver extract as a model biologically derived sample.  Fig. II-6 shows 
the mass spectra of three representative fractions from each protocol.  It is clear that 
the total number of paired peaks detected was much larger and that the number of 
contaminated unlabeled peaks became much smaller when using the improved protocol 
described here (Fig. II-6).  In fact, 12 identical paired peaks were observed in total 
from Fr.1–Fr.10 using the original protocol, whereas 68 identical paired peaks were 
observed in total from EL1–EL7 using the improved protocol (data not shown).  The 
author observed several unlabeled single peaks that were co-eluted with labeled 
peptides even in the ‘Elution’ fractions (for example, see the asterisk in Fig. II-6).  This 
is because, in the case of biologically derived samples, both the number of the proteins 
contained in the samples and the diversity among the peptide sequences was much 
larger.  However, even using an avidin-biotin affinity purification system, it has been 
reported that some untagged peptides can co-elute in the elution fractions.(7)  
Regardless of this, it is clear that the efficiency of enrichment is much improved by the 
use of a phenyl column and that the NBS method is sufficiently sophisticated to be 
applied on a practical level.  By further fractionating each eluate from the phenyl 
column using HPLC and a C18 capillary column, the author observed more than 1000 
paired peaks in total derived from one sample (unpublished results). 
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Figure II-6.  Overall comparison of the original and improved protocols.  Samples were prepared as 
described in Sample preparation for ‘overall comparison assay’ according to the original protocol (a) or the 
improved protocol (b), respectively, and subjected to MALDI-TOFMS analysis.  Mass spectra of three 
fractions of each (Fr.5–Fr.7 in (a) and EL3–EL5 in (b), respectively) are shown. Thick half circles indicate 
NBS-labeled paired peaks with differences of 6 m/z units.  The asterisk indicates a peak corresponding to 
a peptide with amino acid sequence VTYVDFLAYDILDQYR, derived from the tryptic digest of mouse 
glutathione S-transferase Mu 1. 
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In conclusion, The author has analyzed improvements to the NBS protocol and 
demonstrated the effectiveness of the new protocol.  There were two basic 
improvements to the original procedure: the use of urea and/or guanidine hydrochloride 
as a denaturant and improved enrichment of labeled peptides by the use of a phenyl 
column.  The improved protocol resulted in reduction of sample loss throughout the 
procedure (which should result in improvements in the sensitivity), reduction of peaks 
larger than 57 m/z units without any additional sample manipulation, improvement in the 
quantitative recovery, and reduction of overall working time.  The use of a phenyl 
column resulted in reduction of contamination by unlabeled peptides in the elution 
fractions, increased recovery of the labeled peptides, elimination of the desalting step 
by differential elution of salts and labeled peptides, larger capacity compared to an 
affinity or antibody column, and fractionation of individual labeled peptides to some 
extent.  In addition to the improvements detailed above, the derivatized MALDI peaks 
that were previously observed at positions lower by 16 or 32 m/z units, which seemed to 
be derived from the NBS moiety, can be suppressed by the use of the new matrix. 
(Chapter I)  The use of this matrix as a co-matrix with 4-CHCA also improved the 
sensitivity with which NBS labeled peptides were detected.  In conclusion, the 
combination of all of these improvements allowed us to achieve a much more accurate 
and thorough analysis of samples using the NBS method.  However, it was necessary 
to improve the sensitivity of the NBS method further to analyze biological samples 
efficiently.  Then, in Chapter III, the author describes a novel approach for enhancing 
the sensitivity and the selectivity of the NBS-labeled peptide detection by using a new 
matrix (3-hydroxy-4-nitrobenzoic acid) for MALDI-TOF MS analysis. 
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Chapter Ⅲ: Selective detection of NBS-labeled peptides by MALDI -TOF 
MS using a novel matrix  
 
III-1 Introduction 
In vitro labeling methods, such as the NBS method, are becoming increasingly useful 
for quantification of proteins expressed in cells.  However, two problems still must be 
overcome.  One is that the number of peptides to be analyzed is on the order of 105 or 
more after tryptic digestion of a cell lysates. (1)  The second is that if there is an 
extreme difference in the amounts of a protein between two samples to be compared, 
the peaks will appear in mass spectra as a single peak instead of a pair of peaks labeled 
with either a heavy or light reagent.  These false singlet peaks are difficult to 
distinguish fromunlabeled single peaks without sequencing, because more than 80% of 
the peaks correspond to unlabeled peptides. (1)  Thus, an enrichment system for the 
labeled peptides is required to reduce the complexity of the analysis and to improve its 
efficiency.  The author presents here a simple method to significantly improve the 
sensitivity of the NBS method, in which selective detection of labeled peptides is 
achieved by changing the matrix from CHCA to 3H4NBA, or to a comatrix consisting of 
3H4NBA plus CHCA, for MALDI-TOF MS analysis.  The predominant peaks detected 
in samples without purification using these matrices correspond to labeled peptides, 
which are clearly detected in samples after purification.  This method also effectively 
suppresses peaks corresponding to unlabeled peptides, which were not removed during 
the enrichment process. 
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III-2 Materials and methods 
III-2-1 NBS-labeling of model peptides 
Ten micrograms of ACTH (5–10) peptide (EHFRWG; purchased from BACHEM, 
Bubendorf, Switzerland) was suspended in 50 mL of 70% acetic acid solution containing 
20 equiv. of NBSCl (12C6-NBSCl, light form; purchased from Tokyo Kasei Kogyo, Tokyo, 
Japan), and incubated at room temperature for 1 h with gentle mixing. After the reaction, 
the NBS-labeled peptides were desalted by ZipTip µ-C18 (Millipore, Bedford, MA, USA) 
according to the manufacturer, and were eluted with 2 µL of 0.1% TFA solution 
containing 50% ACN twice.  As a control sample the unlabeled peptide was prepared 
in the same way without NBSCl. Both peptides were mixed and subjected to 
MALDI-TOF MS analysis. 
 
III-2-2 NBS-labeling of proteins followed by tryptic digestion 
The mixture of proteins containing bovine a-lactalbumin, rabbit 
glyceraldehyde-3-phosphate dehydrogenase, chicken lysozyme, and chicken 
ovalbumin: (25 mg each, purchased from SIGMA, Steinheim, Germany) was labeled 
with NBSCl according to the improved method (17).  In brief, each mixture containing 
100 mg of proteins was denatured by an 8 M urea solution containing 5 mM EDTA and 
labeled with either 13C6-NBSCl (heavy form) or 12C6-NBSCl (light form) at room 
temperature for 1 h, respectively.  Next, both NBS-labeled (heavy and light) proteins 
were mixed and desalted. After lyophilization, both samples were dissolved in an 8 M 
urea solution (50 mM Tris-HCl, pH 8.8, 8 M urea), reduced, and alkylated with 4 mM tris 
(2-carboxyethyl) phosphine and 10 mM iodoacetamide, respectively, and then 
submitted to tryptic digestion.  The digests were used for MALDI-TOF MS analysis with 
or without further purification of samples.  For MALDI-TOF MS, 2 µg of tryptic digest 
was desalted with ZipTip µC18, and one-eighth of the eluate was analyzed. 
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III-2-3 Nitrotyrosine-containing peptides derived from nitrated lysozyme 
One milligram of lysozyme (ca. 70 nmol) was reacted with a 20 times molar excess of 
tetranitromethane (270 µg, 1.4 nmol) for 1 h at 47C [9, 10]. The reaction mixture was 
passed through a column of Sephadex G-25 (1.0 cm 15 cm) to remove the 
tetranitroformate that was produced.  The nitrated lysozyme was subjected to trypsin 
digestion and a portion of the digest corresponding to 14 µg was lyophilized and 
dissolved in 50 µL of a 0.1% TFA solution, desalted by ZipTip µC18, and then subjected 
to MALDI-TOF MS analysis. 
 
III-2-4 MALDI-TOF MS analyses 
Mass spectra were obtained by AXIMA-CFR plus, AXIMACFR (MALDI-TOF mass 
spectrometers; Shimadzu, Kyoto, Japan/Kratos, Manchester, UK), and 
AXIMA-quadrupole IT (QIT) (MALDI-QIT TOF mass spectrometer; Shimadzu/ 
Kratos).  These mass spectrometers are equipped with a nitrogen laser emitting at 337 
nm, and analyses are performed in the positive ion reflectron mode. External calibration 
was carried out using both ACTH (1–7) and bradykinin (18–39) (both purchased from 
SIGMA).  On each well of the MALDI target plate, 0.5 mL of sample solution was 
spotted and 0.5 µL of matrix solution was spotted over the dried sample.  Each matrix 
solution was prepared by dissolving each chemical in 0.1% TFA solution containing 50% 
ACN at a concentration of 10 mg/mL (2,5-dihydroxybenzoic acid (DHB), 
a-cyano-3-hydroxycinnamic acid (3-CHCA), CHCA, 3H4NBA, 4-hydroxy-3-nitrobenzoic 
acid (4H3NBA), 4-nitroaniline (4NA), 2-nitrophenol (2NP), and 2,5-dinitrophenol 
(25DNP)) or at a saturated concentration (,10 mg/mL: 4-nitrobenzoic acid (4NBA), 
2-hydroxy-4-nitrobenzoic acid (2H4NBA), 2,4-dinitroaniline (24DNA), and 
2-bromo-4,6-dinitroaniline (2B46DNA)).  To prepare a comatrix solution of CHCA and 
3H4NBA, equal volumes of each corresponding solution prepared as above were mixed.  
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All of the m/z values presented in this report are theoretical monoisotopic masses of 
single positive-charge ions, which correspond to the lowest-mass isotope.  
 
III-2-5 Definition of selectivity index 
We defined a “selectivity index” for each matrix as the relative signal intensity ratio of 
NBS-labeled peptide to nonlabeled peptides, based on the standard signal intensity 
ratio obtained using CHCA.  The following formula is used for 
calculation of a selectivity index.  For example, the selectivity index of 3H4NBA (SH) is 
determined as SH = Av. (LH/LC)/Av. (NH/NC).  Here, each symbol represents the 
following: SH, the selectivity index of 3H4NBA; Av. (LH/LC), an average of LH/LC; Av. 
(NH/NC), an average of NH/NC; LH, absolute intensity of each NBS-labeled peptide 
detected using 3H4NBA; LC, absolute intensity of each NBS-labeled peptide detected 
using CHCA; NH, absolute intensity of each nonlabeled peptide detected using 
3H4NBA; and NC, absolute intensity of each nonlabeled peptide detected by CHCA. 
The selectivity index of DHB (SD) is also calculated as SD = Av. (LD/LC)/Av. (ND/NC). 
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III-3 Results and Discussion 
III-3-1 Analysis of NBS-labeled peptides using a MALDI-QIT mass spectrometer 
(AXIMA-QIT) and selected matrices 
AXIMA-QIT is a MALDI-TOF mass spectrometer equipped with a QIT for MSn analysis. 
In this type of mass spectrometer, the molecules that have been ionized by the MALDI 
method are introduced into a quadrupole trap, and then isolation and collision of 
precursor ions followed by MS/MS analyses are performed. Therefore, the time required 
for a generated ion to reach the detector and undergo measurement is two or three 
orders of magnitude longer than that required by MALDI-TOF MS without IT equipment.  
Therefore, when a “hot” matrix such as CHCA is used for the analysis, the ionized 
molecules tend to have excess internal energy that causes them to gradually 
self-degrade while they are held in the trap. Because of this, it is recommended that 
DHB should be used as a “cool” matrix instead of CHCA.  When NBS-labeled peptides 
derived from a tryptic digest of model proteins were analyzed by QIT using DHB as a 
matrix, the mass spectrum differed from that obtained by AXIMA-CFR using CHCA as a 
matrix.  In the spectrum obtained using QIT, pairing peaks with a difference of 6 or 12 
m/z units identified the paired peaks representing NBS-labeled peptides, but most of 
these paired peaks appeared at m/z values that were lower than the expected values by 
14, 16, 30, or 32 m/z units, and this difference seemed to be a consequence of 
fragments of the nitro groups (Fig. III-1A).  The use of DHB was deemed inappropriate 
for measuring NBS-labeled peptides for QIT, so the author searched for other cool 
matrices that could be used with QIT for the detection of NBS-labeled peptides.  After 
evaluating several candidate compounds, the author found that 3-CHCA and 3H4NBA 
are effective matrices, and they detect NBS-labeled peptides with comparable 
sensitivity (Fig. III-1-B and C). 
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III-3-2 Specific detection of NBS-labeled peptides using 3H4NBA as a matrix 
The author examined the effectiveness of the matrices described above, including 
CHCA and DHB, in analyzing NBS-labeled peptides by AXIMA-CFR, a MALDI-TOF 
mass spectrometer without IT equipment. A mixture was prepared containing equivalent 
amounts of an NBS-labeled ACTH peptide (residues 5–10) and its unlabeled 
counterpart as test samples.  When CHCA was used as a matrix, both labeled and 
unlabeled peptides were detected with almost the same intensity (Fig. III-2B).  In the 
case of DHB, the unlabeled peptide gave the dominant signal, whereas the labeled 
peptide was hardly detectable, except for small derivatized peaks that were smaller than 
the expected m/z by 14 or 30 units, as shown in Fig. III-2A.  This phenomenon was 
identical to what the author observed with QIT (Fig. III-1A).  The incompatibility of DHB 
and NBS-labeled peptides is thought to result from MALDI ionization mechanisms, 
rather than from the IT technique.  Both labeled and unlabeled peaks were detected 
with similar intensities using the 3-CHCA matrix, as in the case of CHCA matrix (Fig. 
III-2C). However, in the case of 3H4NBA, completely opposite results were obtained in 
comparison with the DHB matrix results (Fig. III-2D).  The labeled peptide peak was 
dominantly detected, but the unlabeled peak and the 14 and/or 30 m/z units smaller 
Figure III-1. Different effect of matrices on 
MALDI-QIT-TOF MS analysis of NBS-labeled peptides.  
NBS-labeled peptides were enriched from tryptic digests of 
a mixture of four model proteins (ovalbumin, 
glyceraldehyde-3-phosphate dehydrogenase, lysozyme, 
and a-lactalbumin) according to the NBS improved protocol, 
and a portion of the eluate was subjected to MALDI-QITTOF 
MS analysis with AXIMA-QIT. Matrices used were DHB (A), 
3-CHCA (B), and 3H4NBA (C). Closed circles indicate the 
peaks corresponding to NBS-labeled peptides detected at 
the expected positions, and open circles indicate the peaks 
corresponding to fragments of NBS-labeled peptides. 
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peaks were only weakly detected or were barely discernible.  A similar tendency was 
observed for QIT (data not shown), showing that these selective ionizations and 
detections occur during the MALDI process, but not during ion trapping.  On the basis 
of the above results, the author next analyzed tryptic digests of NBS-labeled proteins 
using 3H4NBA as a matrix.  The sample was a peptide mixture derived from four 
proteins, as shown in Fig. 1, but the tryptic peptides were not purified to make the 
NBS-labeled peptides sample. A portion of the sample desalted with ZipTip was 
analyzed by MALDITOF MS.  Both NBS-labeled paired peaks and unlabeled single 
peaks were detected using the CHCA matrix (Fig. III-3B), whereas unlabeled single 
peaks and labeled paired peaks that were smaller by 14 and/or 30 m/z units were 
mainly detected using the DHB matrix (Fig. III-3A).  When the matrix 3H4NBA was 
used for detection, NBS-labeled paired peaks were observed almost exclusively, while 
unlabeled single peaks and the smaller labeled paired peaks were hardly observed at all 
(Fig. III-3C).  These results suggest that selective detection of NBS-labeled peaks from 
a mixture of labeled and unlabeled peptides can be achieved by using 3H4NBA as a 
matrix.  The author proposes that such specificity can be quantified by use of a 
“selectivity index” (details in Section 2).  The selectivity index for each matrix was 
determined using four peaks (one for NBS-labeled and three for nonlabeled peptides) 
from Fig. 2 and 19 peaks (ten for NBS-labeled and nine for nonlabeled peptides) from 
Fig. 3: SH = 8.46 (Fig. 2) and 9.28 (Fig. 3), SD =0.043 (Fig. 2) and 0.22 (Fig. 3).  That 
is, the selectivity index of 3H4NBA is nearly 10 whereas that of DHB is approximately 
0.1.  This indicates that 3H4NBA (or DHB) enables the labeled peptides to be observed 
at ten times larger (or smaller) intensity than CHCA, assuming that unlabeled peptides 
are detected at the same intensity by both matrices.  
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III-3-3 Characteristics of nitrobenzene derivatives as matrices 
In the MALDI process, the matrix plays a key role by incorporating and isolating analyte 
molecules in its bulk crystal; thereafter molecules are released into the gas phase 
concurrently with matrix desorption upon laser-energy absorption, and finally they are 
ionized by ion-molecule reactions in the laser plume.  Therefore, a good combination 
of matrix and analyte and/or an appropriate preparation of the sample mixture are key 
requirements for a successful MALDI-TOF MS analysis (for review [11–13]).  The 
author next searched for the basis of the selectivity of this specific combination of the 
NBS-labeled derivatives and 3H4NBA, on the basis of their structural aspects and noted 
that nitrobenzene is the common skeleton for both NBS and 3H4NBA, as shown in Fig. 
Figure III-2. Specific detection of NBS-labeled peptides by 
MALDI-MS analysis using the 3H4NBA matrix.  
A mixture of 12C6-NBS (light)-labeled and unlabeled ACTH 
(5–10) peptides was measured by MALDI-TOF MS 
(AXIMA-CFR) using DHB (A), CHCA (B), 3-CHCA (C), and 
3H4NBA (D) as a matrix, respectively. Marks indicated are as 
follows: closed circle, a peak corresponding to the NBS 
(light)-labeled ACTH (5–10) peptide (m/z 984.55); open circles, 
peaks that correspond to 16 or 32 m/z units smaller than 
NBS-labeled ACTH (5–10); open arrow head, peaks 
corresponding to the unlabeled ACTH (5–10) peptide (m/z 
831.39). 
 Figure III-3. Specificity of 3H4NBA for selective detection 
of NBSlabeled paired peaks in a mixed sample.  
A mixture of NBS labeled and unlabeled peptides was 
prepared from the tryptic digest of four model proteins and 
was subjected to MALDI-TOF MS analysis. Matrices were 
DHB (A), CHCA (B), and 3H4NBA (C).  Mass spectra 
ranging from m/z 900 to 1050 and from m/z 1450 to 1600 are 
amplified by five-fold along the y-axis.  Closed circles 
indicate the paired peaks of NBS-labeled peptides having a 
difference of 6 or 12 m/z units at the expected positions, and 
open circles indicate the pairs of peaks derivatized from NBS 
labeled paired peaks. Open arrowheads indicate the 
unlabeled peptides. 
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III-4.  To address whether this could be a key factor in the selective detection seen in 
MALDI-TOF MS analysis, the author examined other nitrobenzene derivatives as 
matrices. The author chose a number of mono- and dinitro aromatic compounds having 
functional groups, such as carboxyl, hydroxyl, amino, sulfate, or aldehyde or their 
combinations, that are capable of transferring protons in the MALDI ionization process.  
Our results indicated that many nitrobenzene derivatives could function as matrices, 
and they were effective in the selective detection of NBS-labeled peptides in 
MALDI-TOF MS analysis, although their sensitivities were rather low (Fig. III-5).  
Among the nitro-chemicals tested so far, 3H4NBA is the best matrix for detecting NBS 
peptides, due to its sensitivity and specificity. 
 
 
 
                              
 
         NBS-Trp                                 3H4NBA 
Figure III-4. Structures of the NBS-labeled indole ring of tryptophan and of 3H4NBA.  
Moieties corresponding to nitrobenzene are highlighted in bold. 
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Figure III-5. Specific detection of NBS-labeled peptides using various nitrobenzene derivatives as a 
matrix.  
4.5 mg of ACTH (5–10) peptide was labeled with 12C6-NBS (light) and purified on a C18 RP column 
(Michrome) using HPLC equipment (Shimadzu).  NBS-ACTH (5–10) and unlabeled ACTH (5–10) were 
dissolved in a 0.1% TFA solution containing 50% ACN, respectively.  A mixture of NBS-labeled and 
unlabeled ACTH (5–10) peptides (A–E, 2.5 pmol each; F–J, 0.25 pmol each) was prepared and subjected 
to MALDI-TOF MS analysis using CHCA (A, F); 4NA (B); 4NBA (C); 2NP (D), 25DNP (E); 3H4NBA (G); 
2H4NBA (H); 24DNA (I); and 2B46DNA (J) as a matrix, respectively. Marks indicated are as follows: closed 
circle, a peak corresponding to the NBS (light)-labeled ACTH (5–10) peptide (m/z 984.55); open circles, 
peaks that correspond to 16 or 32 m/z units smaller than NBS-labeled ACTH (5–10); open arrowhead, 
peaks corresponding to the unlabeled ACTH (5–10) peptide (m/z 831.39). 
 
III-3-4 Specific detection of a nitrotyrosine-containing peptide using the 3H4NBA 
matrix 
The author next examined whether nitrobenzene-containing compounds other than 
NBS-labeled peptides can also be detected with specific selectivity using the 3H4NBA 
matrix. The peptides containing a nitrotyrosine (3-nitrotyrosine) residue, which is one of 
the most common nitrobenzene-containing substances that exists in living organisms, 
were examined to see whether they were selectively detected by MALDITOF MS 
analysis using 3H4NBA as a matrix.  To create these types of peptides, lysozyme 
nitrated by tetranitromethane was digested with trypsin and prepared for analysis.  In 
preparing the sample, the nitration reaction was intentionally not allowed to proceed to 
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completion, so the sample included nitrotyrosine-containing peptides, 
tyrosine-containing peptides, and other peptides without tyrosine residues.  As a result, 
the mass spectrum obtained using 3H4NBA showed that the peaks corresponding to 
peptides containing nitrotyrosine residues were stronger than those of non-nitrated 
peptides, and the selectivity was the same or somewhat higher compared to the case of 
the NBS-labeled peptides (Fig. III-6 lower panels).  The author also noted that peaks 
smaller by 16 or 32 m/z units than the primary nitrotyrosine-containing peaks, which are 
apparently caused by loss of oxygen from nitro groups, as in the case of NBS-peptides, 
were also only weakly observed in the mass spectrum of 3H4NBA.  Highly reactive 
nitrogen species (RNS) such as peroxynitrite react with phenyl groups of tyrosine 
residues in a protein to generate 3-nitrotyrosines [14].  A tyrosine residue may also be 
a target for phosphorylation, which plays a critical role in signal transduction, cell death, 
and various other cellular events.  For these reasons, nitrotyrosine residues 
have received attention not only as targeted biomarkers indicating RNS but also as 
functional groups correlating with diseases and cancer.  The methods described here 
should prove advantageous in studies of nitrotyrosine or RNS. 
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Figure III-6. Selective detection of nitrotyrosine-containing peptides using 3H4NBA as a matrix.  
A tryptic digest of nitrated lysozyme was desalted using ZipTip m-C18 and peptides were eluted with 4 mL 
of a stepwise gradient of increasing ACN (10, 20, 30, 40, and 50%) containing 0.1% TFA. Of these eluates, 
10% (A, B) and 30% (C, D) ACN eluates were subjected to MALDI-TOF MS analysis using CHCA (A, C) 
and 3H4NBA (B, D) as a matrix, respectively.  Greek numbers indicate the peaks corresponding to the 
peptides with sequence and theoretical monoisotopic masses as follows: (i) HGLDNYR, 874.42; (i*) 
HGLDNY*R (Y* represents a nitrotyrosine residue), 919.41; (ii) GTDVQAWIR, 1045.54; (iii) 
FESNFNTQATNR, 1428.65; (iv), NTDGSTDYGILQINSR, 1753.84; (iv*) NTDGSTDY*GILQINSR, 1798.83.  
Asterisks denote the peaks that correspond to nitrotyrosine-containing peptides.  Open circles indicate the 
peaks that correspond to 16 or 32 m/z units smaller than the peaks with an asterisk. Lower two panels 
contain expanded views of A and B ranging from m/z 850 to 960 (left) and of C and D ranging from m/z 1740 
to 1820 (right). 
 
III-3-5 Practical use of 3H4NBA as a matrix 
Although the 3H4NBA matrix has advantages in the detection of peptides containing a 
nitrobenzene ring by MALDI-TOF MS, it also has drawbacks of lower sensitivity and 
shotto-shot reproducibility, which resulted in quick signal decay.  The CHCA matrix has 
no selectivity for a peptide with a nitrobenzene ring, but it is highly sensitive, it is easy to 
search for “sweet” spots, and it is stable for signal detection even when multiple shots 
are taken from one spot.  The author next used a comatrix of CHCA and 3H4NBA, 
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because it is known that some combination of two or more matrices (chemicals) can 
result in improved performance in MALDI-TOF MS analysis [15].  As shown in Fig. III-7, 
the signal intensity improved in comparison with the CHCA matrix, while the selectivity 
of 3H4NBA for labeled peptides was roughly retained.  Somewhat continuous signal 
detection from one spot has also been achieved.  The comatrix of CHCA and 3H4NBA 
is especially effective for detecting samples containing a small amount of protein.  For 
example, the author picked up ten NBS-labeled peaks (1198.5, 1204.5, 1244.5, 1250.5, 
1299.4, 1311.4, 1353.6, 1359.6, 1478.6, and 1484.6), which were clearly detected in all 
three MS spectra, and obtained their S/N values.  The average S/N value for the 
comatrix (175.2) is about four times higher than that of CHCA (42.3) and that of 
3H4NBA (47.8).  This indicates that the sensitivity of detection was much improved by 
use of the comatrix.  The recommended ratio for mixtures is 1:1 v/v, because the 
author does not want the characteristics of either comatrix component to predominate 
over the other.  The author next examined comatrices of CHCA with various other 
nitrobenzene compounds.  When each compound was used as a single matrix, its 
sensitivity for detection was very low (Fig. III-5), but the comatrices with CHCA resulted 
in higher sensitivity and selectivity, similar to the results for the comatrix of CHCA and 
3H4NBA (data not shown). 
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Figure III-7. Improvement of utility using a comatrix of 3H4NBA with CHCA. 
 A tryptic digest of four-model proteins containing NBS-labeled and unlabeled peptides was prepared and 
desalted by using ZipTip m-C18. One-thousandth of the ZipTip eluate was subjected to MALDI-TOF MS 
analysis. Matrices were CHCA (A), 3H4NBA (B), and a comatrix of CHCA, and 3H4NBA (mixed in a 1:1 
ratio) (C). Closed circles indicate the paired peaks of NBS labeled peptides having a difference of 6 or 12 
m/z units at the expected positions.  Open arrowheads indicate the unlabeled peptides. 
 
III-3-6 Discussion 
The method developed here of using 3H4NBA and combining it with CHCA to make a 
comatrix has several advantages.  Firstly, the selective detection of NBS-labeled 
peptides from an unpurified tryptic digest can now be achieved (Fig. III-3).  Secondly, 
nonpaired labeled peptides derived from a protein that exists only in either sample can 
be discriminated from unpurified nonlabeled single peaks (see Fig. III-8).  Thirdly, 
when used as a comatrix with CHCA, the sensitivity of peak detection is increased in 
comparison with the use of 3H4NBA alone, and even with that of CHCA alone (Fig. III-7).  
Fourthly, peaks that are 16 or 32 units smaller than the NBS labeled and 
nitrobenzene-containing peaks are suppressed, thus simplifying the mass spectra (Figs. 
1–3, 5, and 6).  Fifthly, it can be determined which peaks correspond to 
nitrotyrosine-containing peptides, which are found in many proteins (Fig. III-6 (ii)).  
Finally, the combinations of matrices and analytes that confer selectivity of detection for 
specific substances in MALDI-TOF MS analysis might prove useful in basic studies of 
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the MALDI process.  In MALDI-TOF MS analysis, peptides containing tryptophan 
residues may be prominently detected by conventional methods using the CHCA matrix 
(Fig. III-6). However, the detection of these peptides was not enhanced by use of the 
3H4NBA matrix.  In contrast, although the NBS moieties of NBS-labeled cysteine are 
removed by reduction and replaced by carbamidomethyl groups in the NBS method [4], 
specially constructed peptides containing NBS-labeled cysteines were detected 
selectively using the 3H4NBA matrix (data not shown).  These results indicate that 
selectivity of the detection originates not merely in the aromaticity of tryptophan or NBS 
but also in the nitrobenzene structure of NBS or nitrotyrosine.  One interesting 
observation is that DHB has a “reverse” or “negative” specificity for detection of 
NBS-labeled peptides.  That is, NBS-labeled peptides are detected with lower intensity 
than unlabeled peptides. This indicates that factors other than the nitro group contribute 
to this specificity, because both CHCA and DHB lack a nitro group.  One possible 
reason for this specificity is that DHB has only two hydroxyl groups in addition to a 
benzene ring and a carboxyl group, whereas CHCA has unsaturated bonds in both the 
cyano group and the olefin moiety.  Thus, these unsaturated electrons can make 
resonance with electrons in benzene ring, and similar interactions could occur as in the 
case of nitrobenzene.  Regarding this speculation, the author found an interesting rule 
that all compounds having nitro groups, which showed clear selectivity as listed in Fig. 
III-5, have at least one functional group in either the ortho- or para-position against the 
nitro group.  These results suggest that electrons of the substituted groups influence 
the electron cloud of the nitrobenzene, and these may eventually influence the 
co-crystallization of matrix and analyte, which must be a key step in the specific 
selectivity of MALDI-TOF MS analysis.  Therefore, it may be interesting to calculate the 
electron density of each chemical and examine its relevance to the selectivity, as this 
seems to be significant.  In the MALDI-TOF MS analysis of NBS-labeled and 
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nitrotyrosine-containing peptides, several peaks were observed at positions smaller by 
16 or 32 m/z units than the original peaks (in the case of CHCA) and by 14, 16, 28, 30, 
32 m/z units (in the case of DHB).  However, these peaks were not observed on 
ESI-MS (LCQ Deca XP plus, Thermoelectron), and therefore the author expects that the 
fragments were generated in the process of MALDI.  Because the nitrobenzene and its 
substituents absorb the energy of an UV laser commonly used in MALDI apparatus, 
analytes having nitrobenzene groups are thought to be energized by UV-laser irradiation 
and degraded.  When the nitrobenzene compounds such as 3H4NBA are used as the 
matrix, the matrix surrounding the analytes may perform a buffering action to prevent 
analytes against absorption of the laser energy.  Regarding the assignment of these 
fragment peaks, the author speculates that the peak smaller by 16 m/z units arises from 
production of the relatively stable nitrosyl group (-NO) by deletion of oxygen from the 
nitro group, but the author cannot determine the molecular species corresponding to the 
other fragment peaks.   
It has been reported that some matrices and/or their combinations are useful for 
detection of specific substances, as seen in the case of DHB to detect phosphorylated 
peptides and oligosaccharides. (13)  However, the method reported here, using 
3H4NBA as a matrix, is significantly more specific in that target substances are easily 
detected in mixed samples, and are often the predominant peaks. Moreover, even in 
cases where 3H4NBA or some other nitrobenzene chemicals by themselves are not 
ideal matrices for a particular application, they can be used as comatrices with CHCA, 
and this may confer selectivity for specific substances.  Therefore, if one chooses a 
chemical having affinity to both CHCA and the analyte, as in the case of 3H4NBA, it may 
effectively function as a “selective comatrix” with CHCA.  It should be noted that the 
method described here has some limitations.  The detection is selective for labeled 
over unlabeled compounds by a factor of about 10, but it is not exclusive.  Therefore, if 
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an unlabeled peptide is present in the sample with a ten-fold excess over the labeled 
peptides, it may be detected as the strongest peak. Furthermore, the selectivity 
decreases if the laser power is stronger than the optimum level, or if the mass of a 
labeled analyte to be focused is relatively large.    Nevertheless, this method will 
provide useful tools for analysis of specific compounds and will allow development of 
new applications in protein analysis. 
 
    
 
The improvements shown in this chapter and Chapter II resulted in an expansion of 
dynamic range of measurement.  By combining the NBS method with HPLC, an 
automatic spotter, MALDI-TOF MS, and an analytical software, the author constructed a 
system called the “NBS Biomarker Discovery System”.  In Chapter IV, the author 
applied the analysis system to CRC (colorectal carcinoma) clinical samples to the 
discovery of drug target and/or biomarker candidates for CRC. 
 
 
 
 
 
 
 
Figure III-8. Schematic mass spectrum showing 
the discrimination of single peaks between 
NBS-labeled and unlabeled peptides by using a 
3H4NBA matrix.  
Closed circles indicate the paired peaks of 
NBS-labeled peptides. Asterisk 1 represents an 
NBS-labeled single peak derived from a protein that 
exists only in either sample, while asterisk 2 
represents a contaminating unlabeled single peak. 
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Chapter IV: An application of the NBS method to proteomic profiling of 
human colorectal carcinoma for biomarker discovery 
 
IV-1 Introduction  
Colorectal carcinoma (CRC) is the third most common type of cancer and the second 
leading cause of cancer death in developed countries.  Over the past two decades, the 
clinical test for CRC has utilized carcinoembryonic antigen (CEA) as a marker protein.  
However, most positive cases are found in patients with advanced cancers or even 
metastases.  For example, the positive detection ratio of CEA in patients with 
metastatic cancer generally ranges from 70% to 80%, whereas it decreases in patients 
with both locally recurrent and early cancers. (1-3)  CEA has not been proven effective 
as a screening marker for early-stage cancers, and its applications have been limited to 
the detection of advanced cancers.  This supports the need to develop novel CRC 
biomarkers to improve the accuracy of diagnosing CRC.  Recently, various 
approaches involving transcriptome analysis have been extensively applied in an effort 
to identify novel diagnostic markers for CRC. (4, 5)  However, mRNA expression levels 
do not necessarily correlate with protein expression.  Hence, direct analysis of proteins 
is indispensable for the discovery of novel biomarkers. 
Most proteomic approaches involving CRC tissues have been performed by 
2D-PAGE in combination with MS, and some successful results have been obtained 
(6-10).  However, it is still difficult to perform comprehensive proteome analysis, as this 
method has several technical limitations (11).  Therefore, the author developed and 
improved the NBS method for global quantitative proteome analysis as shown in 
Chapter I, Chapter II and Chapter III.  In this method, labeled peptides after enzymatic 
digestion are subjected to HPLC separation, while intact proteins are analyzed directly 
using the 2D-PAGE.  These two different methodologies can detect different sets of 
proteins, so the NBS method can complement other methods such as 2D-PAGE. 
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The primary advantage of this new method is that it reduces the number of peptides, 
measured by selecting NBS-labeled tryptophan-containing peptides from bulk tryptic 
digests.  This is advantageous because tryptophan residues are the least abundant 
amino acid in proteins, yet they occur in a large proportion of proteins. (12)  Another 
advantage of this method is the special matrix used for MALDI-TOF MS measurement, 
which can detect the NBS-labeled peptides and with high sensitivity. (Chapter III)  
From these reasons, the author believes this method can improve proteome mining by 
increasing the dynamic range of detection and that it shows promise for quantitative 
proteome analysis. (13-15)  Here, the author applied this NBS method to analyze 
clinical samples from CRC patients in order to discover novel biomarker candidates. 
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IV -2 Materials and Methods 
 
IV-2-1 Tissue samples 
Twelve primary colorectal cancer specimens and corresponding normal colonic mucosal 
specimens were obtained from surgical resections from March, 2003 to November, 
2004. All patients with tumors were diagnosed at advanced stages, and none of the 
adenomas were contained in a cancerous component.  All normal tissues were 
histopathologically confirmed as cancer-free. None of the patients were treated with 
preoperative chemotherapy or radiotherapy.  The samples were stored in RNAlater 
(Qiagen, Valencia, CA) at -20˚C after sampling.  This study was approved by the 
Institutional Review Board of Osaka University and informed consent was obtained from 
each patient. 
 
IV-2-2 Sample preparation 
Frozen tissue samples were homogenized in 500 µL of lysis buffer A (50 mM 
Tris-HCl at pH 8.0, 100 mM NaCl, 5 mM EDTA, 1 mM PMSF, 1 µg/mL leupeptin, and 5 
µg/mL aprotinin) on ice using a Sample Grinding Kit (GE Healthcare, Buckinghamshire, 
UK).  Homogenates were centrifuged at 100,000 × g for 60 min and supernatants were 
obtained as the cytosolic fraction (CF).  Pellets were washed twice with lysis buffer A 
and homogenized in 500 µL of lysis buffer B (2% CHAPS, 9 M urea, 50 mM Tris-HCl at 
pH 8.0, 100 mM NaCl, 5 mM EDTA, 1 mM PMSF, 1 µg/mL leupeptin, and 5 µg/mL 
aprotinin); homogenates were centrifuged at 100,000 × g for 60 min. Supernatants were 
obtained as the 2% CHAPS-soluble fraction (CSF).  These fractionated samples were 
precipitated using the 2D-Clean-Up Kit (Bio-Rad, Hercules, CA) and resuspended in 8 
M urea and 5 mM EDTA.  After centrifugation at 10,000 × g for 5 min, supernatants 
were recovered and subjected to NBS reagent labeling.  Protein concentration was 
determined by BCA Protein Assay (PIERCE, Rockford, US) using BSA as a standard. 
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IV-2-2 NBS reagent labeling, peptide fractionation and MS measurement 
NBS reagent labeling was performed according to the manufacturer’s protocol 
(13CNBS stable isotope labeling kit-N; Shimadzu Biotech, Kyoto, Japan).  Normal and 
tumor tissue samples (100 µg each) were labeled with isotopically light and heavy NBS 
reagent, respectively.  NBS-labeled samples were then mixed, reduced, alkylated and 
digested by trypsin.  NBS-labeled peptides were enriched from tryptic digests and 
fractionated using Phenyl sepharose, as described previously (Chapter II). The resulting 
seven fractions were combined into three fractions and subjected to reverse-phase 
liquid chromatography (LC-10ADvp µHPLC System; Shimadzu), as described 
previously (13). Eluates were automatically deposited onto MALDI target plates by the 
LC spotting system (AccuSpot; Shimadzu). These samples were automatically analyzed 
by MALDI-TOF MS (AXIMA-CFR Plus; Shimadzu / Kratos, Manchester, UK). (13)  
 
IV-2-3 Relative quantification and identification of differentially expressed 
proteins in CRC 
Relative quantification of each NBS-labeled peptide pair was performed using TWIP 
Version 1.0 (Dynacom, Kobe, Japan), referring to a monoisotopic mass list from 
MASCOT Distiller Ver. 1.1.2 (Matrix Science).  The author previously demonstrated 
that quantification errors (%) using a model protein mixture were less than 4%. (13)  
Thus, peptide pair ratios larger than 1.5-fold, or smaller than 0.66, were set as threshold 
values for significant differences.  A threshold value for the occurrence was set to 70% 
of all the CRC patient samples in which peptide pairs were detected. In this manner, 
candidate peptides were selected and further subjected to MS/MS analysis 
(AXIMA-QIT-TOF; Shimadzu / Kratos). (13)  Proteins were identified by the MASCOT 
MS/MS Ion Search algorithm (Version 2.0; Matrix Science) using mass lists generated 
by MASCOT Distiller.  The Mascot search parameters were as follows: trypsin 
digestion allowing up to two missed cleavages, fixed modifications of 12CNBS (or 
 71 
13CNBS) and carbamidomethyl (C), variable modifications of oxidation (M), peptide 
tolerance 0.3 Da and MS/MS tolerance of 0.5 Da.  Search results having p-values less 
than 0.05 were judged as positive identifications. 
 
IV-2-4 Western blot analysis 
Total protein extracts (20 µg; CF or CSF) from the tumor and corresponding normal 
tissue samples of each patient were separated on 10% or 15% SDS-polyacrylamide 
gels. Proteins were then transferred to a nitrocellulose membrane and prestained 
SDS-PAGE standards (Bio-Rad) were used to estimate their molecular weights.  The 
following primary antibodies were used: mouse anti-human Zyxin (ZYX), polyclonal 
(Abnova, Taipei, Taiwan), mouse anti-human RAN, monoclonal (Abcam, Cambridge, 
UK), mouse anti-human S-adenosylhomocysteine hydrolase (AHCY), polyclonal 
(Abnova), rabbit anti-human reticulocalbin 1 (RCN1), monoclonal (Abnova), rabbit 
anti-human galectin1 (LGALS1), polyclonal (Abcam), and rabbit anti-human Vimentin 
(VIM), polyclonal (Abcam).   Nitrocellulose membranes were incubated with diluted 
antibody solution for 2 h at room temperature. After washing in PBS, the membranes 
were incubated at room temperature for 1 h with HRP-conjugated sheep anti-mouse 
IgG antibody (GE Healthcare) for ZYX, RAN and AHCY, or HRP-conjugated donkey 
anti-rabbit IgG antibody (GE Healthcare) for RCN1, LGALS1 and VIM. Primary antibody 
dilutions were: anti-ZYX (1:500); anti-RAN (1:1000); anti-AHCY (1:1000); anti-RCN1 
(1:1000); anti-LGALS1 (1:1000); and anti-VIM (1: 1000).  Secondary antibody dilutions 
were anti-mouse IgG (1:4000) and anti-rabbit IgG (1:10000). Proteins were then 
visualized by ECL Plus detection reagents (GE Healthcare), exposed to X-ray film 
(Kodak, U.S), and the protein band densities were quantified using “CS Analyzer v3.0” 
software (ATTO, Tokyo).  Used membranes were stained with 0.2% CBB R-250 in 
40% MeOH, 10% AcOH for 5 minutes and destained with 90% MeOH, 2% AcOH for 15 
minutes to confirm equal protein loading and blotting (data not shown). 
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IV-2-5 Immunohistochemical staining 
Ten percent buffered formalin-fixed paraffin-embedded sections were prepared from 10 
surgically resected cancers.  Tissue specimens from these same cancers were also 
used for proteomics analyses. The streptavidin-biotin immunoperoxidase complex 
method was used for immunohistochemical analysis.  Briefly, 4-µm slices of tissue 
section were deparaffinized and incubated with 0.03 mol/L citrate buffer (pH6.0) and 
heated to 98°C for 40 min for antigen retrieval.  Endogenous peroxidase activity was 
blocked with 0.3% hydrogen peroxide and 0.1% sodium azide in distilled water for 15 
min. After three rinses in phosphate-buffered saline pH 7.2 (PBS), 10% bovine serum 
(Wako, Osaka, Japan) was applied for 10 min to block non-specific reactions.  
Sections were incubated with the primary antibody for 60 min at room temperature.  
Primary antibodies for immunohistochemical staining were the same as those used in 
the WB analyses.  After washing in PBS, the sections were treated with biotinylated 
sheep anti-mouse IgG (Amersham, London, U.K.) for ZYX, RAN and AHCY or 
biotinylated anti-rabbit IgG (Nichirei, Tokyo, Japan) for RCN1, LGALS1 and VIM for 15 
min.  After washing in PBS, the sections were reacted with streptavidin-biotin 
peroxidase complex (Dako, Copenhagen, Denmark) at 1:300 dilution for 15 min.  The 
peroxidase reaction was visualized by incubating the sections with 0.02% 
3,3’-diaminobenzidine tetrahydrochloride in 0.05M Tris buffer (pH 7.6) with 0.01% 
hydrogen peroxide for 3 min.  Sections were then counterstained with hematoxylin. 
Negative control sections were tested using normal mouse or rabbit serum instead of 
the primary antibody.  Tissue sections of normal liver (for AHCY), skin (for VIM), lymph 
node (for LGALS1) and testis (for RAN, RCN1, and ZYX) were prepared as positive 
controls according to the manufacturers’ recommendations or previous publications.  
All slides were evaluated by a blinded pathologist.  For each immunohistochemical 
analysis the mean intensity of the tumor cells or stromal cells was evaluated in 
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comparison with the positive controls as follows: (a) weak, 1+; (b) moderate, 2+; (c) 
strong, 3+. 
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IV-3 Results and Discussion  
IV-3-1 Proteomic profiling and identification of differentially expressed proteins in 
CRC tissues 
Differential proteome analysis between CRC and normal tissues from each patient was 
performed using the NBS method (Fig. IV-1-(A)). This analysis was performed using CF 
and CSF samples from each of the 12 patients.  After a series of experiments, 
including NBS labeling, peptide fractionation and MS measurement, 2600– 3000 paired 
peaks were observed per analysis.  In this method, the relative ratio of expression for 
each protein is calculated from the relative ratio of peak intensity (or area) in each 
pair-peak (NBS-labeled peptides).  Following this relative quantification, pair-peak lists 
were evaluated (see Materials and Methods) and 320 pairs were judged to have 
significant differences in protein expression and to occur with significant frequency in 
patients.     
 
Figure IV-1 Proteomic analysis of CRC tissue samples by the NBS method.                       
A schematic drawing of NBS analysis (A) and a typical example of MS (B) and MS/MS     
(C) spectra of an NBS-labeled peptide (HWILPQDYDHAQAEAR) from RCN1 are shown. 
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After these peaks were subjected to MS/MS analysis, 226 decent MS/MS spectra were 
obtained, and 156 search results (138 identical peptides) were judged to be positive 
identifications.  This corresponded to 128 proteins, with 71 up-regulated and 57 
down-regulated, as listed in Table IV-1.  Their subcellular localizations are shown in 
Fig. IV-2.  The proportion of cytoplasmic proteins identified using CF analysis was 
nearly half (45.2%), whereas CSF analysis indicated a proportion of less than a quarter 
(22.2%).  In contrast, the proportion of extracellular and plasma membrane proteins 
identified using CSF analysis (27.0%) was much larger than that identified using CF 
analysis (16.4%). Most of the proteins were identified from either CF analysis or CSF 
analysis, and only a few from both (65, 55 and 8 proteins were identified from CF only, 
CSF only or both fractions, respectively).  This means that CF / CSF fractionations 
were successfully achieved and that these fractionations improved the proteome 
coverage.  NBS labeling followed by MS analyses was carried out twice for all samples 
to evaluate experimental variations (Fig. IV-3).  Correlation coefficients calculated for 
each of the 12 patient samples were all above 0.95, indicating this quantitation method 
was reliable.  
In this study, the author focused on 23 up-regulated proteins whose mRNA expression 
was also up-regulated, as determined by cDNA microarray analysis (unpublished data). 
The author selected six of these proteins (ZYX, RAN, RCN1, AHCY, LGALS1, and VIM) 
for further characterization, using the criteria that they had not been well studied in 
relation to CRC and that they have distinct features. 
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Table IV-1 Differentially expressed proteins in CRC tissues 
Protein name 
a)
Average  
T/N ratio 
Average Log2 
(T/N ratio) ± 
SD 
 
Occurrence 
in patients 
(%) 
b)
Fraction 
Previously 
reported in 
CRC 
Up-regulated proteins in CRC tissues 
Alpha1 acid glycoprotein 2.5 1.3±1.0 9 /11 (81%) CF  
Alpha 1 acid glycoprotein type 2   
c)
NC 
c)
NC  10 CF, CSF (8) 
Alpha-tubulin 2.0 1.0±0.54 9 /9 (100%) CSF  
Beta-tubulin 2.1 1.1±0.36 8 /9 (89%) CSF  
Apurinic endonuclease 2.0 1.0±0.47 12 /12 (100%) CF  
Calumenin  2.7 1.4±0.86 10 /10 (100%) CSF  
Chaperonin1   2.3 1.2 ±0.46 11 /11(100%) CSF (6), (9) 
Clathrin heavy polypeptide  1.7 0.78 ±0.78 7 /9 (89%) CSF  
Clathrin light polypeptide A  3.2 1.7 ±1 10/ 11 (91%) CSF  
Complement factor H  2.1 1.1±0.33 9 /10 (90%) CF,CSF  
Cysteine rich intestinal protein 1  1.7 0.78±0.51 8 /9 (89%) CSF (6), (9) 
Cytokeratin 18 2.8 1.5 ±0.99 10 /12 (83%) CSF  (10) 
Enolase 1  2.1 1.1 ±0.92 9 /10 (90%) CF,CSF  (7) 
Ezrin  2.3 1.2±0.6 8 /10 (80%) CF  
F-box protein 40 2.5 1.3±0.61 11 /12 (91%) CSF  
Fibrinogen gamma 2.2 1.2 ±0.5 9 /10 (90%) CF  
Fk506 Binding Protein 1A 2.2 1.2 ±0.5 9 /10 (90%) CF  
Galectin 1 2.1 1.1±0.39 9 /11(81%) CSF  
Glutathione peroxidase 1 1.8 0.81±0.37 8 /10 (80%) CF  
Glycyl tRNA synthetase 
c)
NC 
c)
NC  8 CF    (10)    
Glyceraldehyde-3-phosphate dehydrogenase 2.0 1.0±0.82 8 /10 (80%) CF           
Golgi complex-associated protein 1 2.2 1.1±0.73 8 /9 (89%) CF           
Heat shock 70kD protein 9B 2.8 1.5±0.85 8 /9 (89%) CF           
Heat shock protein 27 2.1 1.1±0.34 10 /12 (83%) CF  
Heparan sulfate proteoglycan 2 2.5 1.3±0.59 8 /9 (89%) CSF  
Heterogeneous nuclear ribonucleoprotein H2 
c)
NC 
c)
NC  9 CSF  
High density lipoprotein binding protein 2.1 1.1 ±0.25 8 /8 (100%) CSF   
HLA-C  2.1 1.1±0.55 7 /8 (88%) CF  
Hypothetical protein FLJ38663 2.2 1.1 ±0.87 7 /9 (78%) CF  
Inorganic pyrophosphatase  2.5 1.3±0.76 10 /11 (90%) CF (6), (8) 
Membrane-bound C2 domain-containing 
protein 
2.0 0.98±0.31 8 /9 (89%) CSF  
Mitogen inducible gene 2 protein 1.9 0.94±0.7 7 /9 (78%) CF  
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6-Phosphogluconolactonase    2.0 0.99±0.78 9 /10 (90%) CF  
Plastin 2 2.4 1.2 ±0.49 10 /10 (100%) CF  
Plectin 1 2.0 1.0±0.8 8 /10 (80%) CSF  
Proteasome subunit p58 2.1 1.1±0.4 8 /8 (100%) CSF  
Protein tyrosine phosphatase, receptor type c 
c)
NC 
c)
NC  8 CSF  
Protein tyrosine phosphatase, receptor type, α 
c)
NC 
c)
NC  8 CSF  
Pyruvate kinase 3  1.9 0.93±0.4 11 /12 (92%) CF (6) 
RAB18, member RAS oncogene family  2.7 1.5 ±0.86 10 /12 (83%) CSF  
RAB22A  1.9 0.94±0.73 7 /10 (70%) CSF  
RACK1 2.0  1.0±0.32 10 /10 (100 %) CF  
Radixin 1.8 0.84±0.76 8 /12 (73%) CF  
RAN, member RAS oncogene family  2.0 0.99±0.67 9 /11 (81%) CF  
Reticulocalbin 1 3.4  1.8±0.96 9 /10 (90%) CF  
Rhodanese; thiosulfate sulfurtransferase 1.9 0.95±0.66 7 /10 (70%) CF  
Ribonuclease RNase A family 3 
c)
NC 
c)
NC  8 CSF  
Ribosomal protein L13 3.4 1.8 ±0.98 10 /10 (100%) CSF  
Ribosomal protein L27a  2.1 1.0 ±0.71 8 /11 (73%) CSF  
Ribosomal protein L4 2.0 1.0 ±0.64 9 /11 (82%) CSF  
Ribosomal protein S18  2.8 1.5 ±0.46 10 /10 (100%) CSF   
Ribosomal protein S29  2.0 1.0 ±0.47 7 /8 (88%) CSF   
Ribosome binding protein 1  1.8 0.87±0.34 10 /11(91%) CF (7) 
S adenosylhomocysteine hydrolase  2.3 1.2 ±0.79 10 /11 (90%) CF  
S100 calcium binding protein A9  2.2 1.2 ±0.7 9/ 11 (82%) CF (9) 
Solute carrier family 25, member 5  2.2 1.1±0.7 8 /9 (89%) CSF  
Solute carrier family 3, member 2 2.0 1.0±0.31 8 /9 (89%) CSF  
Splicing factor 3B, subunit 3  2.8 1.5±0.99 9 /10 (90%) CF (7) 
Splicing factor, arginine/serine-rich 3 (SRp20) 2.3 1.2±0.52 7 /8 (88%) CF  
TLS protein 
c)
NC 
c)
NC  9 CSF  
Transgelin   2.1 1.1 ±0.78 7 /9 (78%) CF (8) 
Transgelin 2  2.3 1.2 ±0.32 10 /10 (100%) CF (6) 
Triosephosphate isomerase 1    2.0  0.99±0.92 10 /12 (83%) CF, CSF (6), (8) 
Tumor rejection antigen 1  
c)
NC 
c)
NC  8 CSF (6) 
Ubiquitin activating enzyme 1 2.1 1.1 ±0.47 9 /10 (90%) CF  
Ubiquitin isopeptidase T 2.3 1.2±0.6 9 /10 (90%) CSF  
U5 snRNP-specific protein, 116 kD  2.5 1.3±0.71 9 /11 (82%) CSF  
Vimentin 2.5 1.3 ±0.39 9 /9 (100%) CSF (6) 
Vitronectin  2.1 1.1 ±0.8 7 /8 (88%) CSF  
XTP3 transactivatied protein A 2.4 1.3 ±0.52 9 /10 (90%) CF  
Zyxin 2.2 1.1 ±0.7 9 /10 (90%) CF  
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Down-regulated proteins in CRC tissues     
Abhydrolase domain containing 14B 0.39 -1.4± 0.55  8 /8 (100%) CF  
ADP ribosylation factor like 10C  0.27 -1.9±1.1  7 /8 (88%) CSF  
Aldehyde dehydrogenase 2 0.42 -1.3±0.54 7 /8 (88%) CF  
Alpha 1 antitrypsin  0.37 -1.5±0.78  8 /11 (73%) CF,CSF  (8) 
Alpha-actinin 1, 4 0.46 -1.1±0.52  7 /8 (88%) CF  
Annexin A2 isoform 2 0.41 -1.5±0.90  9 /11 (82%) CSF (6) 
ATP synthase, H+ transporting, mitochondrial 
F0 complex, subunit d  
0.34 -1.6±1.2  8 /11 (73%) CSF  
ATP binding cassette transporter subfamily A 
member 12  
0.36 -1.5±0.68  9 /9 (100%) CSF  
Calnexin 0.23 -2.2±0.82  10 /10 (100%) CF,CSF  
Calreticulin  0.48 -1.1±0.53  7 /7 (100%) CSF (6) 
Carbonic Anhydrase Ⅱ 0.1 -3.3±1.1  7 /7 (100%) CF (10) 
Carbonyl reductase 1 0.54 -0.9±0.24  8 /8 (100%) CF  
Cathepsin S  0.43 -1.2 ±0.68  10 /10 (100%) CSF (7) 
Collagen type 12 alpha-1 0.43  -1.2 ±00.63  7 /7 (100%) CSF  
Collagen type 14 alpha-1 
c)
NC 
c)
NC  7 CSF  
Creatine Kinase-B 0.50  -1.0± 0.33  8 /8 (100%) CF (8) 
Cysteine rich protein 1 0.33 -1.6±0.47  7 /7 (100%) CF  
Desmoglein 2  
c)
NC 
c)
NC  8 CSF  
Dynein light chain 1 0.48 -1.1±0.53  10 /10 (100%) CSF  
Endoplasmic-reticulum-lumenal protein 29  0.42 -1.2±0.46  7 /7 (100%) CSF  
Endoplasmic-reticulum-lumenal protein 46 0.42 -1.2±0.75  8 /9 (89%) CF  
Enoyl CoA hydratase 1 0.34 -1.6±0.94  9 /9 (100%) CF  
Eukaryotic translation elongation factor 2  0.51 -0.98±0.39  8 /8 (100%) CF  
Eukaryotic translation initiation factor 3 subunit 
6 
0.33 -1.6±0.65  12 /12 (100%) CF  
FHL1 (skeltal muscle LIM-protein) 0.34 -1.6±0.84  7 /9 (78%) CF (7) 
Filamin A 0.4 -1.3±0.99  8 /9 (89%) CF, CSF (7) 
Filamin B  0.39 -1.4±0.62  11 /11(100%) CF  
Gelsolin isoform a 0.44 -1.2±0.45  9 /10 (90%) CF  
Glucosamine-fructose-6-phosphate 
aminotransferase 1 
0.34 -1.5±0.77  7 /7 (100%) CF  
GTP-binding protein Rab1 0.59 -0.77±0.33  7 /10 (70%) CF  
Haptoglobin  0.46 -1.1±0.69  8 /11 (73%)  CF (7) 
Heterogeneous nuclear ribonucleoprotein A2 
/B1 
0.42 -1.3±0.39  7 /7 (100%) CF (7) 
Hydroxymethylglutaryl-CoA synthase, 0.30 -1.7±0.83  9 /10 (100%) CF  
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mitochondrial  
Isocitrate dehydrogenase 1  0.09 -3.5±1.6  9 /10 (100%) CF  
JM5 protein  0.55 -0.86±0.32  7 /9 (78%) CSF  
Major vault protein  0.47 -1.1±0.44  7 /7 (100%) CSF  
MHC class I antigen  0.53 -0.92±0.50  7 /9 (78%) CF  
Myeloperoxidase 0.46 -1.1±0.34  7 /7 (100%) CSF  
Myosin, heavy polypeptide 14  0.38 -1.4±0.74  7 /7 (100%) CSF  
Myozenin 3  0.47 -1.1±0.57  9 /9 (100%) CSF  
NADH Ubiquinone oxidoreductase subunit B13  0.38 -1.4±0.71  8 /10 (80%) CF (8) 
Normal mucosa of esophagus specific 1  0.25 -2.0±1.0  8 /8 (100%)  CSF  
Olfactomedin 4  0.46 -1.1±0.55  7 /7 (100%) CSF  
Phosphoenolpyruvate calboxykinase 2 0.44 -1.2±0.58  7 /8 (88%) CF (10) 
Phosphoglycerate mutase 1  0.23 -2.1±1.5  8 /9 (89%) CF  
Proline arginine-rich end leucine-rich repeat 
protein  
0.34 -1.6±0.84  11 /11 (100%) CSF  
Protein kinase C and casein kinase substrate in 
neurons 2  
0.49 -1.0±0.48  8 /8 (100%) CSF  
Pyridoxine 5-prime-phosphate oxidase 0.27 -1.9±1.6  9 /12 (75%) CF  
Raf kinase inhibitor protein  0.41 -1.3±0.62  10 /12 (83%) CF  
Ras associated protein Rab5B  0.42 -1.2±0.40  7 /7 (100%) CF  
Retinoblastoma binding protein 4, 7 0.43 -1.2±0.56  7 /7 (100%) CSF  
Succinate dehydrogenase complex,subunit 
A,,flavoprotein 
0.43 -1.2±0.56  7 /7 (100%) CF,CSF (7), (8) 
TNRC15 protein  0.29 -1.8±1.1  8 /9 (89%) CF  
Transferrin 0.46 -1.1±0.61  9 /9 (100%) CF  
UDP-glucose dehydrogenase 0.36 -1.5±0.62  7 /7 (100%) CF  
Valosin containing protein 0.49 -1.0±0.33  10 /11(91%) CF  
Villin 1 0.13 -2.9±1.9  8 /9 (89%) CF (7) 
a) An average (T/N ratio) is calculated by exponential transformation of an average Log2 (T/N ratio) 
b) Fraction; CF: cytosolic fraction, CSF: 2 % CHAPS-soluble fraction 
c) NC; not calculated.  This is because a protein is exclusively detected in CRC (or normal) tissues. 
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Figure IV-2  Classification of differentially expressed proteins in CRC tissues.  
Identified proteins that were differentially expressed in CRC tissues are classified into categories based 
on their subcellular localization.  Proteins identified in the cytosolic fraction (CF) (A), and those 
identified in the 2% CHAPS-soluble fraction (CSF) (B) and the total of 128 proteins (C) are represented 
graphically.  
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Figure IV-3 Correlation among the two tests by the NBS method. 
The x-axis shows the ratio of protein quantity in colorectal carcinoma (T) to normal colon (N) in 
experiment 1, in Log2 scale. The y-axis shows the ratio in experiment 2. 
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IV-3-2 Verification of results obtained from global quantitative proteome analysis 
by the NBS method 
Although the good reproducibility and reliability of the NBS method have been 
demonstrated previously (Chapter I, Chapter II, 13) and were also demonstrated in the 
above analyses, the author carried out western blot (WB) analysis to verify our results 
using an independent method.  Using the same fraction (CF or CSF) and the same 
CRC patient samples used in the NBS analyses, WB analyses were performed for the 
six selected proteins (Fig. IV-4).  Generally, high T/N ratios were again observed in WB 
analyses, though the precise ratio was sometimes unmatched in one-to-one data 
comparison with the NBS analysis.  The inconsistency sometimes observed between 
NBS and WB data may be due to the different assay methods (see Discussion).  
Because the high T/N ratios observed in the NBS analyses were confirmed by WB 
analyses for all six selected proteins, these proteins were further evaluated by 
immunohistochemical staining analysis.  
 
 
 
Figure IV-4  Western blot 
analysis for data verification. 
 
Western blot (WB) analyses 
were performed using matched 
pairs of normal (N) and tumor 
(T) tissues to detect the 
following proteins: ZYX, RAN, 
RCN1, AHCY, LGALS1, and 
VIM.  CF samples were used to 
detect the four proteins in the 
upper panel and CSF samples 
were used to detect the two 
proteins in the lower panel.  
The T/N ratios obtained from 
WB and NBS analyses are 
shown below each blot.  The 
average T/N Ratio for each 
protein was calculated from the 
ratio in each sample where both 
NBS and WB data were 
obtained.  N.C.: not calculated.  
N.D.: not detected.    
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IV-3-3 Further validation by immunohistochemical staining 
Finally, immunohistochemical staining was performed to investigate the localization of 
the six selected proteins and to examine their expression patterns in whole CRC tissues 
(Fig. IV-4).  All of these proteins, in all samples tested, were immunohistochemically 
detected more frequently in CRC tissues than in adjacent normal tissues. Cancer cells 
expressed five proteins (ZYX, RAN, RCN1, AHCY, and LGALS1); RCN1 and AHCY 
were strongly detected and ZYX, RAN and LGALS1 were found at moderate levels, on 
average, in all samples tested, although their expression patterns were not 
homogenous. In particular, RAN, RCN1 and LGALS1 were localized partially in cancer 
cells. On the other hand, normal colorectal epithelial cells expressed only ZYX, RCN1 
and AHCY, and their expression was generally weak. Various stromal cells were positive 
for five proteins (ZYX, RAN, AHCY, LGALS1, and VIM), including leukocytes, blood 
vessels, nerves and fibroblasts. VIM expression was strongly and specifically expressed 
in stromal cells close to the cancer cells. ZYX and LGALS1 were moderately expressed 
in stromal cells generally, and their expression here was as strong as that of cancer 
cells. Stromal cells close to the cancer cells expressed these three proteins more 
intensely than those distant from cancer cells.  Five of the six selected proteins (ZYX, 
RAN, AHCY, LGALS1, and VIM) were expressed not only in cancer cells, but also in the 
surrounding stromal cells.  
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Figure IV-5  Immunohistochemical staining (IHC) for the six selected proteins in CRC tissues. 
Insets show IHC staining of normal colonic tissue.  Bars indicate 20 µm in all figures, including insets 
(Original magnification X140, insets X70).  Each displayed picture (A -F) is a typical example of ten tested 
samples. 
(A) ZYX was expressed in cancer cells as well as in stromal cells close to cancer cells, including leukocytes 
and blood vessels.  Weak ZYX expression was observed in normal epithelial cells and in stromal cells    
distant from cancer cells (Inset). 
(B) RAN was expressed in cancer cells, while normal epithelial cells were negative.  Some leukocytes 
adjacent to cancer cells also expressed RAN.  
(C) RCN1 was expressed in cancer cells and weakly in normal epithelial cells.  No RCN1 expression was 
detected in stromal cells. 
(D) AHCY was expressed in cancer cells and weakly in normal epithelial cells.  Weak AHCY expression 
was observed in stromal cells such as leukocytes and blood vessels. 
(E) LGALS1 was expressed in stromal cells including leukocytes, nerve cells and fibroblasts.  Expression 
in stromal cells adjacent to cancer cells was much stronger.  Some cancer cells expressed LGALS1, 
while normal epithelial cells were negative. 
(F) VIM was strongly expressed in stromal cells including leukocytes, fibroblasts and blood vessels.  
Expression in stromal cells adjacent to cancer cells was much stronger.  Neither normal epithelial cells 
nor cancer cells expressed VIM at all. 
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IV-3-4 Discussion 
The author performed proteomic profiling of CRC tissue samples to identify novel 
biomarker candidates by the NBS method.  Proteins that were differentially expressed 
between tumor and normal tissues, with significant differences in expression and 
affecting most of the patients, were selected and a final set of 128 proteins was 
identified.  Of these, 23% (30 proteins) were reported in earlier proteomic studies on 
CRC. (6-10)  Interestingly, the present study has led to identification of about 100 
novel CRC-associated proteins that have not been reported to associate with CRC 
before.  In this study, two fractions (CF and CSF) were prepared in order to increase 
the range of analyses. Many extracellular and plasma membrane proteins were 
recovered simultaneously and identified in CSF fractions.  CEA, a well-known 
biomarker used for clinical detection of CRC, is a GPI-anchored membrane 
glycoprotein.  It has been suggested that CEA is cleaved by glycosylphosphatidy 
-linositol-phospholipase D (GPI-PLD) and then secreted into blood. (16)  Thus, plasma 
membrane proteins have the best chance of being secreted into circulatory systems, 
along with extracellular proteins.  In other words, plasma membrane proteins and 
extracellular proteins are excellent candidates for biomarker development.  Viewed in 
this context, our report seems to contain many potential CRC biomarker candidates.  
There are some discrepancies between the NBS and WB results (Fig. IV-3; for example, 
AHCY for Patient 5, LGALS1 for Patient 8, VIM for Patient 7).  This probably was due 
to differences in the two analytical methods.  In WB analysis, whole proteins, including 
post translational modifications (PTMs) or alternative splicing variants, can be detected 
by a shift in migration, although subtle differences of molecular weight change caused 
by a small modification or a point mutation are overlooked.  On the other hand, in NBS 
analysis, peptides are detected with a resolution power of less than one Da, although 
PTMs, mutations, and splice variants not present in the NBS-labeled peptides will be 
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overlooked.  Thus, the NBS method by itself is not suitable for a comprehensive 
analysis of PTM moieties of proteins because the coverage of each protein is quite low.  
This is indeed a drawback and a limitation of the NBS method, which must be 
compensated by other methods.  However, global proteome analyses with respect to 
PTMs-proteins can be performed by the NBS method if it is combined with prior 
enrichment of the sample. (15)  Six selected proteins showed high expression levels in 
CRC tissues and occurred with high frequency in CRC patients (ZYX (90% (9/10)), 
RAN (81% (9/11)), RCN1 (90% (9/10)), AHCY (90% (10/ 11)), and LGALS1 (81% (9/11), 
respectively).  These proteins were also selected because they have not been well 
studied in relation to CRC, and so they were considered to be novel biomarker 
candidates.  Each of these is discussed in detail below. 
ZYX is a zinc-binding phosphoprotein that is a member of the LIM protein family. This 
protein is widely expressed in human tissues and is most prominent in lung and colon 
tissues. (17)  It has been suggested that ZYX might enhance hepatocellular carcinoma 
cell migration and intravasation through its action on the actin cytoskeleton, as it 
promotes cell dissemination as a part of integrin-signaling pathways. (18)  However, 
there have been no reports demonstrating an association of ZYX with CRC. In this study, 
we have demonstrated high expression of ZYX in CRC tissues for the first time.  
Moreover, ZYX was highly expressed in both cancer cells and in the surrounding 
stromal cells.  Because this molecule is also strongly expressed in blood vessels in 
close proximity to cancer cells, it might be secreted into the blood of CRC patients.  
RAN is a small GTP-binding protein belonging to the RAS superfamily.  This 
molecule has also proven essential for various mammalian cellular processes, such as 
nuclear-cytoplasmic transport, cell cycle progression, nuclear organization, nuclear 
envelope assembly, mitotic control and genomic instability. (19, 20)  Because genetic 
instability is a major factor in carcinogenesis and development of cancer, this protein is 
 86 
considered to be associated with carcinogenesis.  It has been reported that high-level 
expression of RAN is strongly associated with the prognosis of epithelial ovarian tumors 
[24]. In this study, the author demonstrated its up-regulation in both cancer cells and in 
the surrounding stromal cells.  Taking into consideration these data and previous 
reports, it appears that this protein might be a key molecule in CRC carcinogenesis. 
RCN1 is a calcium-binding protein expressed in the ER.  This protein contains six 
repeats of a domain containing an EF-hand motif, which is considered to play a role in 
Ca2+-dependent cell adhesion. (22)  This protein regulates cadherin expression in 
breast carcinoma and colorectal carcinoma cells (SW480) (23, 24), and high expression 
of this protein in hepatoma cells has been demonstrated. (25)  The author noted for the 
first time high expression levels of this protein in CRC tissue.  In addition, the author 
demonstrated that RCN1 was overexpressed with high frequency only in cancer cells.  
Our data suggest that RCN1 might be a promising candidate for biomarker 
development.  
AHCY catalyzes hydrolysis of S-adenosylhomocysteine (AdoHcy) to adenosine and 
homocysteine.  This enzyme is crucial in the control of transmethylation reactions, and 
a deficiency of this molecule induces hypermethioninemia. (26)  There is little evidence 
indicating any association of this molecule with cancer.  Another proteomics study 
demonstrated up-regulation of AHCY in CRC tissue (8); however, this was not 
characterized further.  The present study utilized IHC to show, for the first time, high 
expression of AHCY in cancer cells and weaker expression in the surrounding stromal 
cells. 
Galectins regulate pleiotropic biological functions involved in cell growth, differentiation, 
adhesion, RNA processing, apoptosis and malignant transformation. (27)  Galectin-1 is 
found extracellularly in many tissues in both normal and pathological conditions, and 
several reports have demonstrated an association of galectin-1 with cancer. (27)  
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Up-regulation of LGALS1 in CRC tumor tissue was found using another proteomic 
approach (28); however, no follow-up studies have been reported to date.  In the 
present study, this protein was strongly expressed in stromal cells adjacent to cancer 
cells, in addition to its up-regulation in tumor tissue. 
VIM is an intermediate filament that represents a third class of well-characterized 
cytoskeletal elements, along with the actins and tubulins.  This protein is considered to 
be a key protein in cell physiology, cellular interactions, and organ homeostasis. (29)  
In previous reports, IHC examination has shown that most cases of primary colonic 
malignant melanoma, which is a rare tumor, were positive for VIM. (30)  In the present 
study, this molecule was strongly expressed in stromal cells in the vicinity of cancer cells, 
and was associated with CRC.  
Analyses of whole tissues including stroma are important to understand cancer 
biology and to discover novel biomarker candidates.  This is because as much as a 
half of tumor tissues are composed of stroma, and cancer cells are frequently 
influenced by this.  Also, stroma cells may be influenced by neighboring cancer cells, 
and changes of the stroma could constitute a “cancer signal”.  IHC experiments in this 
study revealed that two proteins (LGALS1 and VIM) were up-regulated in CRC tissues, 
but they are located primarily in stroma, not in tumor cells.  This observation supports 
the importance of whole tissue analysis.  In addition, it suggests that a proteomic study 
should be compensated and validated by IHC, because it alone does not reveal detailed 
information regarding protein localization, which is required for precise functional 
analyses.  
In this study, proteins up-regulated in CRC tissues, whose mRNA expression was 
also up-regulated, were primarily selected for further studies.  It is natural to focus on 
up-regulated proteins in CRC to identify potential diagnostic biomarkers to achieve early 
detection of CRC.  This set of proteins may include a key protein that is responsible for 
 88 
carcinogenesis.  Considering the above possibility, genes with high mRNA expression 
in CRC are the best targets for gene therapy, such as RNA interference.  This is why 
the author prioritized investigating these proteins over others in this study.  However, 
up-regulated proteins that showed a negative correlation with mRNA expression require 
further investigation because they were detected only by proteomic studies.   
To identify biomarker candidates for early diagnosis, examinations of specimens 
from patients diagnosed at an early stage of disease may be ideal.  However, 
advanced tumor specimens were used in this study for the first screening, as previously 
reported [6-10], partly because it is difficult to obtain enough early stage specimens.  
Although many proteins identified in this experiment may not be applicable to early 
diagnosis, several of them are anticipated to be already altered and to be applicable as 
early stage markers, as proved in earlier studies. (7, 9)  This is why proteins identified 
from advanced stage specimens may still be used as early diagnostic markers.  The 
author is now examining whether selected candidate proteins are detected at 
significantly higher levels in sera of CRC patients in comparison with healthy volunteers.   
The author originally assumed that the term “biomarker” is simply used in clinical 
diagnostic scenes, but it could be used in clinicopathological ones as well.  For 
example, there are few cases in which the pathological diagnosis for cancer is difficult. 
However, it is sometimes difficult to specify the localization of the primary tumor when a 
metastatic focus is first detected in cancer screening. (31)  In such a case, the proteins 
identified in CRC tissues in this study would be very useful to identify the primary site, if 
they were applicable.  The author believes that the present study will contribute to 
future improvements in diagnostic/prognostic applications, understanding of CRC 
carcinogenesis, and the discovery of new therapeutic targets and drugs. 
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General conclusion 
 
In this thesis, the author developed a novel quantitative proteome technique (NBS 
method) in order to discover drug target and/or biomarker candidates for diseases such 
as cancers.  The method is based on labeling with the chemical reagent NBSCl in 
conjunction with tandem mass spectrometry.  In this method, selective introduction of 
the NBS moiety onto tryptophan residues is achieved, and a six Da mass differential is 
generated using 13C6-labeled NBSCl (NBSCl-
13C6) and 
12C6-labeled NBSCl 
(NBSCl-12C6).  The six Da mass differential between the NBS-
12C6-labeled and the 
NBS-13C6-labeled peptides assigns a mass signature to all tryptophan-containing 
peptides in any pool of proteolytic digests for protein identification through peptide mass 
mapping.   
  In Chapter I, using this strategy, the author compared the protein expression in rat 
sera using a normal (control) rat (Crj:-Wistar) and a hyperglycemic rat (GK/Crj).  As a 
result, the stable isotope dilution techniques used in this method provide highly accurate 
relative quantification.  The approach offers a widely applicable means of analyzing 
protein mixtures derived from biological samples, and the method described here 
presents an effective and simplified approach to proteome analysis. 
In Chapter II, the author optimized the procedure in the NBS method by utilizing urea 
or guanidine hydrochloride as a protein denaturant, in conjunction with an improved 
chromatographic enrichment method for the NBS-labeled peptides using a phenyl resin 
column.  By using this new protocol, both sample loss throughout the protocol and the 
elution of unwanted unlabeled peptides was minimized, improving the efficiency of the 
analysis significantly. 
In Chapter III, it was demonstrated that 3H4NBA is a more suitable matrix than DHB 
for detecting NBS-labeled peptides by MALDI-QIT-TOF MS.  Furthermore, 
NBS-labeled peptides were selectively ionized and detected in a mixture of 
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NBS-labeled and unlabeled peptides.  Labeled paired peaks were easily detected 
without enrichment, and non paired labeled peaks were clearly distinguished from 
unlabeled contaminating peptides.  Furthermore, nitrotyrosine-containing peptides 
were selectively detected on the 3H4NBA matrix, while by-product-peaks arising from 
nitrobenzene moieties were suppressed.  The use of 3H4NBA as a comatrix with 
CHCA improved the sensitivity of detection while essentially retaining the selectivity of 
3H4NBA.  The 3H4NBA matrix offers great advantages in terms of simplicity, sensitivity, 
and utility when used for the NBS method and for MALDI-TOF MS analysis applied to 
compounds having a nitrobenzene ring.  The improvements described in Chapters II 
and III resulted in reduced sample loss and increased sensitivity, and as a result, an 
expansion of dynamic range of measurement.  By combining NBS reagents with HPLC, 
an automatic spotter, MALDI-TOF MS, and analytical software, the author constructed a 
system called the “NBS Biomarker Discovery System”.   
In Chapter VI, the author applied the system to proteomic profiling of CRC to identify 
novel proteins with altered expression in CRC.  Each pair of tumor and normal tissue 
specimens from 12 CRC patients was analyzed, and approximately 5000 NBS-labeled 
paired peaks were quantified.  Peaks with altered signal intensities (>1.5-fold) and 
occurring frequently in the samples (>70%) were selected, and 128 proteins were 
identified by MS/MS analyses as differentially expressed proteins in CRC tissues.  
Many proteins were newly revealed to be CRC related; 30 were reported in earlier 
studies of CRC.  Six proteins that were up-regulated in CRC (ZYX, RAN, RCN1, AHCY, 
LGALS1, and VIM) were further characterized and validated by Western blot and 
immunohistochemistry.  All six were found to be CRC-localized, either in cancer cells 
or in stroma cells near the cancer cells.  These results indicate that the proteins 
identified by the system can be novel cancer biomarkers. 
As a result, in this thesis, it was demonstrated that the NBS method provide highly 
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accurate relative quantification using clinical samples and the analysis system is useful 
for the novel biomarker discovery. 
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